Top Rebound 2005-Novavax(NVAX)- CEO kauft dazu... - 500 Beiträge pro Seite (Seite 6)

[2Tuvok]

Bei whyso sollte mal einer klingeln,
hoffentlich hat er kein schwaches Herz.

[AidanQ.]

...war das heute jetzt mehr eine technische reaktion

[nort.]

Antwort auf Beitrag Nr.: 21.093.497 von AidanQ. am 05.04.06 20:43:22

mit Sicherheit, mal sehen wie es diese Woche so ausgeht...

ansonsten dies schon gesehen?

http://phx.corporate-ir.net/phoenix.zhtml?c=71178&p=irol-pre…

http://library.corporate-ir.net/library/71/711/71178/items/1…

nort

[AidanQ.]

...also lag es doch an cel-sci.trotzdem sind rodman & co weiterhin von nvax überzeugt und halten am kz von 10$ fest, sehe ich das so richtig?

[AidanQ.]

..dann sollten die herren und damen von nvax mal eigene gute news veröffentlichen

[AidanQ.]

...da hätten wir ja fast auf th geschlossen.

[mikel_ann]

Positive Entwicklung. Da kehren wohl langsam die Leute
von CVM zurück....

[AidanQ.]

...hoffentlich. und morgen die 7$

[mikel_ann]

Antwort auf Beitrag Nr.: 21.094.658 von AidanQ. am 05.04.06 22:08:59

.. denke das ist abhängig vom Newsfloat.

[[KERN]Codex]

schön schön

[idon]

nana, wer ist denn heute nervös geworden ???


Vaccine Pipeline

Government Funded


Candidate
Stage

HIV/aids VLP vaccine
Non-Human Primate

Pandemic flu VLP vaccine
E-selectin to prevent secondary stroke
Small Animal

Melanoma Vaccine
Phase 1

Severe Acute Respiratory Syndrome (SARS)
Discovery



Partnered or Internally Funded


Candidate
Stage

Trivalent flu VLP vaccine
Discovery

Hepatitis E Virus Vaccine
Phase 3


die Aktie hat noch einen langen Weg vor sich und hat heute bewiesen, dass der Name des Threads wirklich gerechtfertigt ist, den hat whyso (viele Grüsse:kiss extrem gut getroffen

stay strong, stay long (wie meine Frau auch immer zu sagen pflegt ) wünsche euch ne gute Nacht nach der ganzen Aufregung

[e.1]

hallo, ich weiß dies ist der nvax thread.
aber, weiß jemand wass mit dem split bei acacia ist?
im acacia thread wird nix mehr geschrieben, absolute stille ist dort angesagt.
würde mich sehr freuen, wenn jemand etwas dazu sagen kann.

grüße

e.1

[nort.]

Antwort auf Beitrag Nr.: 21.096.239 von e.1 am 06.04.06 07:27:06

Hallo e1,

der Split soll angeblich dieses Halbjahr erfolgen. Es ist ruhig, weil alle zu möglichst günstigen Preisen einkaufen

nort

[e.1]

hallo nort,

vielen dank für deine info.
bin im moment mit mir am grübeln, ob ich nochmal nachlegen soll. ich gehe stark davon aus, dass der split nochml aufschwung geben wird.

gruß
e.1

[kafutznik]

Nachbörslich gestern noch 6,87 mal sehen was heute passiert

[[KERN]Codex]

Einfach der Oberhammer

[AidanQ.]

...und jetzt 6,26$

[gonanotech]

Antwort auf Beitrag Nr.: 21.101.820 von AidanQ. am 06.04.06 13:37:07

Hallo AidanQ.,
da hast du aber mit deiner Meldung die Talfahrt des Kurses hier in Deutschland eingeleitet. Der Handel von 200,265 bzw. 300 Aktien ließ daraufhin den Kurs in Frankfurt auf 5,06 € stürzen. Vorbörslich in USA ein wirklich trauriges Bild, für die angebotenen 100 St. zu 6,30 USD will doch einer wirklich nur 6,12 USD per Stück zahlen.
Sag mal, bist du in Anbetracht eines täglichen Handelsvolumens von ca. 10 Mio. Aktien bei diesen Mikroumsätzen wirklich so beunruhigt?

[AidanQ.]

...naja, die kurse sind ja für jeden einsichtig. wer daraufhin verkauft, wird es sich wohl überlegt haben. ich persönlich bin weniger zittrig. bloss von nachbörslich 6,85$ zu vorbörslich 6,26$ ist schon eine notiz wert,

[hemj79]

UPDATE 1-RESEARCH ALERT-RBC cuts Novavax to "underperform"
....
RBC maintained its $3 price target on the stock.

[[KERN]Codex]

SCHEISSE!!

[Kotzolani]

Novavax and Bharat Biotech Announce Strategic Alliance for Pandemic Influenza Vaccine Development


HYDERABAD, India and MALVERN, Pa., March 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and Bharat Biotech International Limited (BBIL), today jointly announced a strategic alliance to pursue the rapid development of pandemic influenza vaccine for India and certain other south Asian markets. Under the terms of the agreement, BBIL will fund 100% of the pre-clinical and clinical studies for these markets and assist in developing an efficient manufacturing process for the Virus-Like Particle (VLP) based influenza vaccine. BBIL will be responsible for the sale and distribution of the vaccine in India and other surrounding countries. Novavax will receive unrestricted access to all pre-clinical and clinical data generated by BBIL and will receive a double digit royalty on all future sales located within BBIL's geographic territories.

Cases of avian influenza (Bird Flu) in poultry and humans have been occurring sporadically throughout the world, prompting the World Health Organization to call avian flu the greatest concern to human health. There are at least 16 Hemagglutinin and 9 Neuraminidase genes within various subtypes of influenza viruses known to circulate in wild waterfowl, each with the potential to infect and cause severe disease in poultry and humans. Three avian influenza subtypes (H9N2, H7N7, and H5N1) have transmitted to humans in recent years and are considered major threats for a pandemic outbreak.

Novavax's Virus-Like Particle Vaccines use recombinant DNA technology to produce antigenic structures that mimic a virus to produce a protective immune response without the risk of infection or disease. Viral proteins can self-assemble into VLPs when over-expressed in certain cells. The use of VLP technology has already been proven with the success of the Hepatitis B vaccine. In addition, the developmental Human Papilloma Virus vaccines are also based on VLP technology. This is the first time that VLP technology has been applied to create an influenza virus vaccine. The technology is a particularly good fit for addressing pandemic influenza because it obviates the reliance on the supply of embryonated eggs for the production of the vaccine. Novavax has recently adopted a manufacturing process that reduces contamination risk and produces high, cost-effective yields of the influenza VLP vaccine (See Press Releases dated September 13, 2005 and February 28, 2006). In addition, this technology can be used to rapidly create vaccines against emerging threats or new strains of existing pathogens.

Commenting on the agreement, Dr. M.K. Bhan, Secretary, Department of Biotechnology, Government of India said, " This is a very positive development. In the spirit of combining global expertise to collectively combat the threat posed by the rapidly spreading avian influenza virus, the department of biotechnology and the Government of India stand ready to provide all enabling support to ensure the success of this partnership between Novavax and BBIL" .

Dr. Rahul Singhvi, President and CEO of Novavax said, " We are delighted that BBIL has chosen Novavax's VLP and Novasome(R) adjuvant technologies to develop, produce, and distribute a vaccine against H5N1 and other strains of avian influenza for the Indian population. BBIL has established itself as a leader in adopting innovative vaccine technologies as evidenced by their collaborations with Wyeth and Acambis. We believe that by leveraging the clinical, process and manufacturing capabilities of BBIL, we will be able to expedite the development and regulatory approval of our VLP-based pandemic influenza vaccines around the world" .

Dr. Krishna M. Ella, Chairman and Managing Director of Bharat Biotech International Ltd, said " We are extremely pleased to announce this unique partnership between Novavax and BBIL, with the guidance and support of the Department of Biotechnology, Government of India. This agreement between our companies is bigger than just business. It is an attempt to bring together capabilities of two different organizations across the world to address the global public health and economic threat posed by pandemic influenza. Novavax's VLP technology is clearly one of the most effective in addressing emerging strains of the virus and BBIL's proven capabilities in process development, clinical development, and manufacturing infrastructure will help expedite the availability of a VLP-based vaccine for pandemic influenza to the Indian public and the world at large. By joining hands with Novavax, BBIL would be making, in a modest way, its contribution to the cause of Public Health in India and the Developing World" .

This alliance will be overseen by a Steering Committee chaired by Dr. Richard Klausner, eminent scientist and Former Executive Director of the Bill and Melinda Gates Foundation and Former Director of the US National Cancer Institute. Dr. Klausner is a special advisor to both the Government of India and to Novavax, Inc. Commenting on this agreement, Dr. Klausner said " I am heartened by this partnership between Novavax and BBIL. I have had a chance to work with each of these organizations and I know the principals in both firms well. These organizations and their management teams are serious in their commitment and are uniquely suited to develop a vaccine against pandemic influenza. I am confident that by combining their mutual capabilities and by working closely with the Department of Biotechnology, Government of India, they will be more effective in arriving at a solution for the good of public health worldwide" .

About Virus-Like Particle (VLP) Technology

Novavax's VLP vaccine technology utilizes recombinant DNA to present components of the influenza virus in three-dimensional virus-like structures optimized to elicit a protective immune response without the risk of infection and without the addition of chemical adjuvants. Using the proprietary process associated with this VLP technology, Novavax intends to further develop vaccines which can be produced aseptically, thereby reducing contamination risk, while achieving high, cost-effective yields.

About Novavax, Inc.

Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The Company's platforms include the virus-like particle manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes and dendrimers. The Company is developing vaccines against the H5N1 and other strains of avian influenza and human seasonal influenza viruses using its VLPs and Novasomes. Novavax's drug delivery platforms include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, Estrasorb(R). In addition to MNP, Novavax drug delivery technologies include Novasomes (paucillamellar non-phospholipid vesicles) and Sterisomes(R) (subcutaneous depot injection). The company has several products utilizing the MNP technology in various stages of development.

About Bharat Biotech International Inc.

Bharat Biotech International Limited based in Hyderabad, India, is a privately held, multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research. Bharat's state-of-the-art manufacturing plant is the largest of its kind in Asia-Pacific. The first bio-pharma facility in the country to be audited and approved by Korean Food & Drugs Administration (KFDA), it sprawls over a picturesque campus at Genome Valley, Hyderabad. Built with an investment of over INR 1000 million, the facility's manufacturing, control procedures and protocols, conform to the stringent standards laid down by internationally recognized institutions such as USFDA, UKMCA, and WHO. Bharat has set new benchmarks in Innovation and Quality that epitomizes the tremendous progress of Indian biotechnology in the global arena.

Forward Looking Statements

Statements made in this press release that state Novavax's or management's intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners, competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to establish and maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10K for the year ended December 31, 2004 and quarterly reports on Form 10Q for the quarters ended March 31, 2005 and June 30, 2005 and September 30, 2005 incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel [phone] or the SEC at www.sec.gov.

SOURCE Novavax, Inc.

[kafutznik]

Blutbad in Amiland unter 6 Dollar die drehen wieder durch

[AidanQ.]

...was zieht, analysten oder pressemitteilung? 3$ wären echt ein schock

[hemj79]

Kotzolani die News ist vom 6.3. !!!!

[kafutznik]

Antwort auf Beitrag Nr.: 21.103.180 von AidanQ. am 06.04.06 14:52:38

Die Pressemitteilung ist alt

[hemj79]

quelle vergessen:

http://yahoo.reuters.com/stocks/QuoteCompanyNewsArticle.aspx…

[kafutznik]

Antwort auf Beitrag Nr.: 21.103.180 von AidanQ. am 06.04.06 14:52:38

Das gibt heute ein ordentliches rauf und runter ,also drüben wird bis jetzt ordentlich verkauft leider riesen Blöcke mir schwant böses

[Kotzolani]

Antwort auf Beitrag Nr.: 21.103.236 von kafutznik am 06.04.06 14:55:27

sorry leute ich hatte sie gerade erst gefunden...

[AidanQ.]

..käufer und verkäuferverhältnis ausgeglichen, bin gespannt, wie der tag für nvax heute endet

[AidanQ.]

...es soll wohl das gap bei 5,50$ geschlossen werden, heute -10%, echt der hammer

[hemj79]

der Kurs kämpft mir der 6$-Marke! Mal sehen ob er sie wieder knackt...

[tillex]

Die Aktie hat gute Widerstände bei 4,90 und 4,45, in dem Dreh mal über einen Kauf nachdenken.

[hemj79]

Antwort auf Beitrag Nr.: 21.107.594 von tillex am 06.04.06 18:07:34

redest du von EUR oder USD?

[tillex]

Antwort auf Beitrag Nr.: 21.107.771 von hemj79 am 06.04.06 18:16:02

€ , alles darunter wäre ein Witz. Hemsipherx, Combimatrix und die anderen Grippedinger sollten ebenfalls nach oben drehen.

[gonanotech]

Hallo,
will denn nicht mal jemand einen Erklärungsversuch starten, warum Novavax innerhalb einer Woche um ca. 30% gefallen ist. Halten wir hier alle eine Aktie, von der wir so gut wie garnichts wissen. Was bedeutet z.B. die Aussage: "da muß ein gap bei 5,50 USD geschlossen werden"? Ist das was gutes oder was schlechtes.

Mit freundlichen Grüßen

gonanotech

[AidanQ.]

...die 38 ist auch nach unten durchbrochen.test des unteren bollingerbandes wohl wahrscheinlich. wer die nerven hat zu traden, sollte solche situationen der letzten tage ausnutzen.
ansonsten so verhalten wie whyso und einige andere es hier machen.

füße still halten

[nort.]

Antwort auf Beitrag Nr.: 21.109.478 von AidanQ. am 06.04.06 19:39:29

50-MA !!!!! gaaaaaaanz genau beobachten

[AidanQ.]

...punktgenau aufgesetzt. bollinger noch etwas weit. tippe trotzdem auf 5,50$ morgen

[buxte]

Hallo,

habe länger nicht reingeschaut.

Gruß an Alle.

buxte

[nort.]

Antwort auf Beitrag Nr.: 21.111.540 von buxte am 06.04.06 21:47:54

Hi Buxte,

willst wieder mitspielen?

nort

[AidanQ.]

...genau wie gestern abend. zum ende eine kleine schlussauktion

[hemj79]

moin,

wie sieht es heute mir der Charttechnik aus?

[buxte]

Antwort auf Beitrag Nr.: 21.111.651 von nort. am 06.04.06 21:53:31

Kommt darauf an.

der Kurs liegt z.Z. in der Nähe des unteren BBD, läßt also einen Umkehrschluß bis zum Mittelwert zu. Das letzte Mal lag der Kurs am Mittelwert am 14.02. Das könnte also heißen, daß der Kurs sich mehr in Richtung oberes Band bewegt. Dann wäre natürlich ein Einstieg mehr als sinnvoll.
MACD, RSI und Stochastik Slow sehen meiner Meinung nach nicht so gut aus.

Werde heute Abend mal beobachten wo das Ganze hingeht.

Gruß
buxte

[Namaycush]

Hallo Zusammen - ich habe mich auch schon eine Weile nicht mehr zu Wort gemeldet. Für mich aber stimmt die Story weiterhin und ich sehe keinen Grund beunruhigt zu sein. Ich bin seit letztem Jahr dabei und werde weiterhin dabei bleiben. Klar ist es ärgerlich für jene welche den Ausstieg bei 8$ verpasst haben - aber ich bin kein Trader sondern ein Investor. Ich bin im Plus und bleibe weiterhin dabei, bis sich fundamental etwas ändert.

Fahre am Montag zum Fischen in die Ferien und tue dies ruhig und ohne Angst um mein Investment.

Allen schöne Ostern

Namaycush

[kafutznik]

Hoffentlich haben die nicht den Kurs bei 6 Dollar hoch gehalten damit instis aussteigen können das wäre eine katastrophe ,rechne auch damit das wir die 5,40 Dollar noch sehen werden heute,und hoffe das es dann nach oben dreht , bloß nicht unter 5 fallen das wäre es dann wir werden sehen ,komisch ist nur das Novavax nichts schreibt, mir geht das zu schnell runter und der Markt weiß meistens mehr

[AidanQ.]

...ärgerlich ist auch, dass der kurs eingebrochen ist, als die news von cel sci kam. das zeigt, dass viele im amiland nur mit der vogelgrippe spekuliert haben. wenn das so ist, ist die fantasie erstmal raus, es sei denn, nvax bringt demnächst news zum thema. nvax ist extrem gut gelaufen und konsolidierungen um die 50% hatten wir schon mal.

Index Components as of: 04/06/06
Company Name Symbol % Weighting

Immunicon Corp IMMC 4.59%
Acacia Research-Combimatrix CBMX 4.37%
Nanogen Inc NGEN 4.25%
Arrowhead Research ARWR 4.22%
Kopin Corp KOPN 4.17%
Westaim Corp WEDX 4.05%
Veeco Instruments VECO 4.04%
Tegal Corp TGAL 4.02%
Altair Nanotechnologies ALTI 3.87%
Mts Systems MTSC 3.81%
Ultratech Inc UTEK 3.80%
Amcol Intl ACO 3.72%
Fei Co FEIC 3.69%
Pharmacopeia Inc ACCL 3.64%
Harris & Harris Group Inc TINY 3.61%
Headwaters Inc. HW 3.59%
Biosante Pharmaceuticals BPA 3.58%
Novavax Inc NVAX 3.57%
pSivida Ltd. (ADS) PSDV 3.55%
Nanophase Technologies NANX 3.50%
Nve Corp NVEC 3.48%
Symyx Technologies SMMX 3.47%
Lumera Corp LMRA 3.39%
Skyepharma Plc Ads SKYE 3.32%
Cabot Corp CBT 3.23%
Flamel Technologies Ads FLML 3.20%
Jmar Technologies JMAR 2.25%

störend ist auch das neue kurzziel von 3$, ich frage mich , was das soll. nvax ist schuldenfrei, gute pipeline etc.

naja, the trend is your friend und der sagt mindestens 5,50$

[kafutznik]

Höchste Vorsicht Bid in Amiland gerade ebend von 5,98 auf 5,48 runtergesetzt worden nicht ins fallende messer greifen erst muß sich Novavax äußern ist sehr bedenklich das es so runter geht

[AidanQ.]

Antwort auf Beitrag Nr.: 21.116.446 von kafutznik am 07.04.06 10:56:04

...wo holst du dir die vorbörslichen kurse?

[Taras]

Also ich hab

5.43 zu 6.15

[AidanQ.]

http://www.us-aktien.com/realtime.htm

[[KERN]Codex]

Bin Gestern rausgeflogen, hab umgeschichtet in HEB, die haben gegen Abend schön performt, ich komme wieder wenn die Delle weg ist.. scheiss ANAL ysten

[hemj79]

Habt ihr diese Analyse von Rodman&Renshaw schon gesehen?

http://library.corporate-ir.net/library/71/711/71178/items/1…

[AidanQ.]

..wie hoch ist denn gerade das shortvolumen und mit wieviel % sind die insitis noch dabei.

[mikel_ann]

Antwort auf Beitrag Nr.: 21.120.380 von AidanQ. am 07.04.06 14:47:01

Hier fehlt nur eine News. Dann explodiert der Stock.

[mikel_ann]

Wir hatten ein DoppelTop bei 8.30 kombiniert mit
7 Mio zu 5,43 und eine schlechte Analyse und eine Biotech.

Mehr braucht es nicht um den Kurs runterzubringen, oder.

Ich war nicht schnell genug über 7€ zu verkaufen, aber ganz sicher
gebe ich jetzt keine Papiere her. Die Reissleine käme erst
unter 50er MA oder wenn NVAX schlechte News veröffentlicht.

Um hier im grossen Stil einzusteigen ist m.E gut manipuliert worden.

Sobald konkrete Infos zur Impfstoffentwicklung kommen, sind wir
zweistellig. Davon bin ich überzeugt.

Stay Long !

[Vinyard]

Momentan wenn island stimmt schon wieder 6,15 Dollar... es geht wieder bergauf....

[hemj79]

sogar 6,2

[AidanQ.]

...tja, die 6$ sind 'ne starke marke

[mikel_ann]

Antwort auf Beitrag Nr.: 21.122.269 von AidanQ. am 07.04.06 16:05:19

Es scheint, als würden wir heute grün schliessen.

[AidanQ.]

...wäre schön. dow und nasdag drehen aber gerade ins minus

[hemj79]

Was sagen die Charttechniker? Ist es nur eine Gegenreaktion? Oder ist es eine echte Aufwärtsbewegung mit Kaufsignalen...

[derwolf1]

http://www.forbes.com/markets/2006/04/07/novavax-chiron-0407…

...Scheiss Analystenpack die gehören alle verklagt !!!!!

Hoffe für alle hier das es nicht so schlimm kommt....." target="_blank" rel="nofollow ugc noopener">[http://www.forbes.com/markets/2006/04/07/novavax-chiron-0407…

...Scheiss Analystenpack die gehören alle verklagt !!!!!

Hoffe für alle hier das es nicht so schlimm kommt.....

[mikel_ann]

Antwort auf Beitrag Nr.: 21.129.737 von derwolf1 am 08.04.06 10:17:21

Immer mehr bin ich der Meinung, dass dieser Analyst
gekauft ist. Den Beweis hierfür anzutreten ist natürlich
schwer. Hier eine Story von 2001, da wurde VVUS "hochgeschrieben".

Weis jemand was aus <Female Viagra> geworden ist ?

Sicher beruht das gesteckte Ziel von 8 - 10$ auch auf
Zukunftsaussichten, aber die sind immerhin anhand von Zahlen
errechnet. Man muss sich den Werdegang von Ken Trbovich wirklich
mal genauer ansehen.


By Lawrence Carrel Published: December 14, 2001

FORGET ABOUT BUILDING a better mousetrap. Remembering what Viagra did for Pfizer (PFE), investors beat a path to Vivus's (VVUS) door Friday on news that the company has developed a treatment for female sexual dysfunction. The stock rose 37% after Ken Trbovich, an analyst at C.E. Unterberg Towbin, trumpeted the drug and raised his rating to Strong Buy from Buy.

Vivus has been down this road before. It was one of the first companies to come up with an effective treatment for male impotence. But the process proved too invasive for most men, and the company got sidelined by Pfizer and its Viagra. This time, though, companies with rival pharmaceutical solutions for female sexual dysfunction — such as Pfizer and an Eli Lilly (LLY)/ICOS (ICOS) joint venture — have failed to demonstrate benefits in early trials. While those companies relied on pills, Vivus's Alista is a topical treatment believed to increase blood flow to the female genitalia.

Trbovich's rating is based on positive results from a Phase II study of Alista as reported by the company in a Nov. 29 press release. The actual data from the study won't be released until May. But Vivus said the study found statistically significant differences between the responses to Alista and a placebo among 79 patients.

Although the drug needs to go through many more trials, and won't become commercially available before 2005, Trbovich focused on the positives. There's now no product to treat female sexual dysfunction, which is reported to some degree by 43% of all women. That compares with the 31% of men who suffer from some form of erectile dysfunction, and who currently comprise a $1.5 billion market.

Quote
"We previously ignored the potential value of Alista due to the lack of supporting clinical evidence," wrote Ken Trbovich in his report Friday. "Now, Alista appears to be Vivus's lead compound. On its own, Alista could be worth $5 per share, nearly the value we assign to Vivus's other compounds combined."

[idon]

und trotzdem geht sie runter ???????????????

Novavax receives additional government funding for HIV/AIDS vaccine research

NVAX
$5.94
-0.07 -1.2%

Released : Apr 06, 2006 7:53 PM

Novavax, Inc. (NVAX) announced approval from the U.S. National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. National Institutes of Health (NIH), of an additional commitment of approximately $1 million to fund the third year of a 4 1/2 year research program.

Novavax is developing a novel HIV/AIDS virus-like particle (VLP) vaccine as part of an NIH Integrated Preclinical/Clinical AIDS Vaccine Development Program comprised of scientists from the University of Alabama at Birmingham, Emory University, and Harvard Medical School. All three institutions are working with Novavax in a collaboration to accelerate HIV/AIDS vaccine development.

Dr. Gale Smith, vice president of vaccine development, explains, "We believe the only realistic solution to the global HIV/AIDS pandemic is an effective vaccine. Novavax is extremely pleased to be working with such an acknowledged group of world leaders in developing a novel HIV/AIDS vaccine. Our research is based on our insect cell technology for the production of recombinant virus particles that mimic HIV-1, but without the risk of infection."

According to Dr. Beatrice Hahn, one of the principal investigators at the University of Alabama at Birmingham, "Globally circulating strains of HIV-1 are extraordinarily variable, and this diversity poses a major obstacle to AIDS vaccine development. Currently, all candidate vaccines are derived from contemporary HIV-1 isolates, often selected solely based on availability. With VLP vaccines produced by Novavax, we are now testing whether consensus immunogens can elicit broadly cross-reactive immune responses and thus protect against a wide range HIV-1."

In the first 2 years of the program, Novavax developed a process to manufacture HIV-1 VLPs from consensus sequences of the HIV-1 envelope glycoprotein, the principle target for virus neutralization. These synthetic genes were shown to be incorporated into particles that are structurally similar to HIV-1.

Scientists at UAB, Emory, and Harvard discovered that the novel HIV/AIDS VLP vaccines induced a range of immune responses and antibodies in small animals and non-human primates that neutralized both laboratory strains and acute, contemporary HIV-1 isolates. The objectives for the team during 2006 are to maximize efficiency of incorporation of the HIV-1 envelope glycoprotein into particles. Novavax then plans to begin preparations for human clinical trials of an improved HIV/AIDS VLP vaccine.

Novavax's virus-like particle (VLP) vaccines use recombinant DNA technology to produce antigenic structures that mimic a virus to produce a protective immune response without the risk of infection or disease. Viral proteins can self-assemble into VLPs when over-expressed in certain cells. The use of VLP technology has already been proven with the success of the hepatitis B vaccine and more recently with developmental human papillomavirus vaccines.

This is the first time that VLP technology has been applied to create a potential HIV/AIDS vaccine and is the same technology Novavax is using to produce influenza VLP vaccines that are readily adaptable and could be scaled up to meet a surge in demand during a pandemic.

Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies.

This article was prepared by AIDS Weekly editors from staff and other reports. Copyright 2006, AIDS Weekly via NewsRx.com.

Copyright 2006 AIDS Weekly via NewsRx.com


Provider:
NewsRx.com / AIDS Weekly

NVAX war der Meister der News und ist seit zirka drei Wochen wie tot, trotz super News (siehe oben). Instis sind gut eingestiegen, NVAX hat Cash wie nie zuvor, und das war's, jetzt geht's bergab ?????

Bin der gleichen Meinung wie einige bei Yahoo, bald wird richtig die Post hier abgehen. 50MDA müsste sicher gehalten werden.

Hy whyso, wie siehst du die Story??? würde mich freuen, deine Meinung zu erfahren

Greets, Idon

[idon]

Vieleicht kommen ja hier mal pushende News

Pressroom Ready at Bio Conference
by: oldman2001
Long-Term Sentiment: Strong Buy 04/10/06 07:20 am
Msg: 202823 of 202840

The pressroom is available at the Bio conference
http://www.bio.org/events/2006/media/

Pressroom Hours
Sun 9:00 am - 5:00 pm
Mon-Tue 7:00 am - 6:00 pm
Wed 7:00 am - 5:00 pm

Hopefully we'll get some good news!

Novavax is presenting Tuesday 11th at 2:30 pm.

The BIO 2006 Business Forum is a major component of BIO’s Annual International Convention. The forum offers an unparalleled opportunity for pharmaceutical companies, biotechnology companies, academic research institutions and investors from around the world to gather in one place at one time to learn about each other and meet one-on-one to discuss business opportunities of mutual interest.

Könnte also spätestens morgen interessant werden, Greets, Idon

[AidanQ.]

...vorsicht, fallendes messer

[AidanQ.]

...conversion price of $5.46.

[AidanQ.]

...so, die 50 er linie ist auch durch, nächster stop 5$ und danach gute nacht

[nort.]

Antwort auf Beitrag Nr.: 21.146.446 von AidanQ. am 10.04.06 16:28:12

bedenklich, was heute abgeht...

[AidanQ.]

..das kz von 3$ hängt wie eine dunkle wolke über nvax, den analysten sollte man echt kicken

[nort.]

Antwort auf Beitrag Nr.: 21.146.582 von AidanQ. am 10.04.06 16:33:18

abwarten, man weiß nie was seine wirklichen Absichten waren... Auch zwischen den Analysten gibt es gewisse Fehden aus alter Zeit...

[AidanQ.]

...wenn die nächste sl welle bei 5 losgetreten wird, gehts so richtig den bach runter.hat jemand die shortquote?

[nort.]

Antwort auf Beitrag Nr.: 21.146.692 von AidanQ. am 10.04.06 16:38:26

leider keine aktuelle. Da die sonst so stabile 50-MA durchbrochen wurde, gibt es keinen neuen Ansatzpunkt. Letzter Insiderkauf war bei 4$. Die 200-MA ist bei 3,40 $. Alles nicht besonders erfreulich...

[radic]

ab jetzt gestaffelt wieder kaufen, den Tiefpunkt erwischt man eh nicht. Man muss dran glauben und ein paar Monate Zeit haben.

[formentum]

denke jetzt ist der schlechteste Zeitpunkt zu verkaufen, das Risiko liegt nicht allein bei nvax, es wird in den nächsten Tagen die Entscheidung anstehen ob der Vogelgrippehype weiter wieder richtung Norden geht oder das ganze sehr schnell ein Ende haben wird, da sind dann viele Werte abwärts unterwegs.
Können nur hoffen das bald starke News bzw.ganz hart gesagt richtige angsteinflössende Nachrichten über die Birdflu kommen.

[bubu]

Ich habe gekauft, wenn als die Nacht am schwärzesten war.

Schaun mer mal!

Gruß
bubu

[AidanQ.]

...naja, ich halte die füße still und warte. lieber verschenke ich ein paar prozent, als dass ich sie verliere. doch eins ist klar, sollte etwas positiver newsflow kommen, gibt es kein halten mehr

[bubu]

5,07 x 5,08

scheint so, als ob der Boden bei USD 5 hält

Gruß
bubu

[hemj79]

Ich habe ja noch eine kleine Hoffnung das wir über der 50 Tageslinie schließen (circa 5,80 $). Aber da müsste eine positive News her!

[kafutznik]

Könnte heute gut hoch gehen ,wenn die Präsentation gut ausfällt was ich persönlich glaube werde mal heute bis 4,50 Euro einsammeln das kann jetzt ganz schnell hoch gehen ,bei 5,10 Dollar waren fette Käufe mit hohem Volumen die kaufen nicht einfach so das ist fakt, da wollten welche billig rein ihr werdet sehen


NOVAVAX INC Quick Quote: NVAX 5.14 (Even)




Novavax to Present at BIO 2006 Chicago Annual International Convention
4/10/2006

MALVERN, Pa., April 10, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Novavax, Inc. (Nasdaq: NVAX) today announced that Dr. Rahul Singhvi, President and Chief Executive Officer, is scheduled to present at BIO 2006, the Annual International Convention of the Biotechnology Industry Organization, on April 11, 2006 at 2:30 p.m. CDT at the McCormick Place Convention Center located in Chicago, Illinois. Dr. Singhvi will present a case study on Novavax's potential pandemic virus-like particle (VLP) flu vaccine initiative; a new vaccine platform to address the urgent need for a potential pandemic flu outbreak.

-- Results of pre-clinical studies with an avian influenza (pandemic)
H9N2 candidate VLP vaccine
-- Novasomes(R) - a safe, patented adjuvant to help address the need for
antigen sparing
-- Rapid, disposable, scalable manufacturing process to meet vaccine
needs for pandemic flu
-- Comparison of Novavax' VLP technology with other vaccine approaches

About Novavax, Inc.

Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.

About BIO 2006

BIO 2006 will draw 18,000 life science professionals from around the world to network and learn about the future of the industry through an expansive exhibit hall and a series of thought-provoking, educational programs. Sponsored by the Biotechnology Industry Organization (BIO), the 14th annual international convention will continue to take place through April 12, 2006 at Chicago's McCormick Place Convention Center.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.

Forward-Looking Statements

Statements made in this press release that state Novavax's or management's intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners; competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to establish and maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10K for the year ended December 31, 2005 incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel [phone] or the SEC at http://www.sec.gov.

SOURCE Novavax, Inc.

Kathy Hamilton, Novavax Investor Relations, [phone], Email: [e-mail] http://www.prnewswire.com

Copyright (C) 2006 PR Newswire. All rights reserved.

© 2006 Stockgroup Media Inc. | Disclaimer

[mikel_ann]

Antwort auf Beitrag Nr.: 21.154.277 von kafutznik am 11.04.06 08:29:28

Bisher haben solche Präsentationen auf den Kurs keine Auswirkung gehabt. Dennoch ist langsam eine technische Reaktion erforderlich.

Das hier noch grosse reinwollen und die Faktoren für einen Kursverfall sprachen, hatte ich schon früher erwähnt.

Wenn NVAX nicht komplett kaputtgeredet wird, sollte es mittelfristig bergauf gehen.

[kafutznik]

Es wird heute hoch gehen du wirst sehen bis später

[AidanQ.]

...von den indikatoren her sind wir im überverkauften bereich. allerdings ist das volumen viel zu hoch. ohne news wirds wohl erst eine seitwärtsbewegung. aber vielleicht bringt die konferenz heute was gutes

[Schwarzermilan]

Wie weit könnte es wohl noch runter gehen wenn die 5$ durchbrochen werden?Liegen ja gerade bei 5.01

[hemj79]

kleine Erholung bis 5,3$...
Vielleicht gehts noch weiter hoch...
im besten Fall testen wir noch die 50 Tageslinie!

[AidanQ.]

...könnte halten

[buxte]

Antwort auf Beitrag Nr.: 21.156.825 von AidanQ. am 11.04.06 11:23:54

will ja nicht unken, aber nach einer Konferenz ging es immer bergab.

Würde mich freuen, wenn es diesmal anders wäre.

buxte

[AidanQ.]

...nächster stop 4,50$

[2Tuvok]

Antwort auf Beitrag Nr.: 21.166.135 von AidanQ. am 11.04.06 20:19:37

Morgen,Leidgenossen.Ich halte und sehe zu
wie NVAX ins bodenlose fällt,zu blöd die
abzugeben.Man bin ich blöd,naja schöne Ostern.

[Moz68]

Vielleicht ist dies endlich mal ein Grund zum Optimismus. Aus dem Daily Insider Trading Report:

EVANS GARY C (Director) B 25,000 4.95 123,750

[radic]

yep, gute Nachricht.

Oder einfach die alte Regel: kaufen, wenn die Kanonen donnern ( gegen : nicht ins fallende Messer greifen )

Oder hier einfach die Fakten bewerten: sind übrigens die gleichen wie bei 8 Euro. Jedes Gap wird geschlossen, hier ist es vollbracht.

Weglegen

[AidanQ.]

...wenn sich da man nicht gleich das nächste gap auftut. umsatz immer noch zu hoch und auf tagestief geschlossen. technische gegenreaktion ist schon fällig, werden aber die meisten nutzen, um auszusteigen.wann kommen die Q1 zahlen. die nächste dicke unterstützung sehe ich erst bei 4$

[idon]

das ist die erste der guten Nachrichten, wenn EVANS kauft, auch wenn es "nur" 25.000 Stück sind. es werden sicherlich weitere News folgen!!!

Denke,dass es jetzt wieder bergauf geht.

[AidanQ.]

..also

Novavax (NASDAQ:NVAX) closed recently at $4.81 with a volume of 80321 X 100 . My current rating on NVAX is, "Weak Sell".

A "Weak Sell" stock is one that I think will probably move lower, yet the downtrend should be minimal at this point. If you hold the stock and are hoping for a move higher, a "Weak Sell" could be good news.

The "Weak Sell" rating is tricky, though. There are mixed signals that at once show the stock is going lower still, but could stop the drop anytime. It's a signal that says, "Be ready for a change of character".

My least favorite rating is the "Weak Sell" or "Weak Buy". But, on the flipside, the next stop from "Weak Sell" is, "Strong Buy!"

http://www.donharrold.net/ratings/US/NVAX.php#

[AidanQ.]

..burn shorty burn

[hemj79]

5.12$ ... na hoffentlich gehts so weiter!!!

[AidanQ.]

...jetzt noch ein osterei aus der pr-abteilung und es tanzt der hase

[AidanQ.]

...muss ich mich hier alleine freuen

[hemj79]

mensch da bin ich mal ein paar stunden nicht da... und
schon geht die post hier ab! Freu mich auch mit....

[idon]

happy happy

hoffen wir mal, dass es so anhält

[[KERN]Codex]

[e.1]

vielleicht habe ich ja den richtigen moment erwischt. bin zu 5.02 heute mittag wieder eingestiegen. in cbmx auch.

[23_2011]

tag ! hab mich gerad mal angemeldet! feu!
hatte schon angst habe gestern zu 4,03 nachgelegt.
hoffe das war kei fehler


23

[AidanQ.]

..wenn der cheffe selber kauft der wird ja wohl wissen, was seine firma wert ist

[e.1]

spannender bericht über die verbreitung von h5n1 auf phoenix.

ui ui ui

[[KERN]Codex]

thx

[[KERN]Codex]

Azeri bird flu girls discharged as outbreak eases
BAKU, Apr 12 (Reuters) Azerbaijan's Health Ministry said today that a bird flu outbreak was easing in the country and that two teenage girls had recovered sufficiently from the virus to be discharged from hospital.

The two girls from the same family were treated in hospital last month with suspected H5N1 bird flu, diagnoses confirmed by the World Health Organization (WHO).

Azerbaijan's Health Ministry is waiting for results of tests at a British laboratory on samples taken as a precaution from 43 people who had complained of serious cold-like symptoms in recent weeks.

''There have been no further approaches from the population and we are awaiting the results on the 43 people,'' Health Ministry spokeswoman Samaya Mamedova said.

''At the present time in Baku, there are no patients suffering from bird flu or with suspected bird flu.'' The WHO said yesterday that tests had found that the elder girl had the H5N1 strain of bird flu, but she had fully recovered and already been discharged.

That case takes the total confirmed bird flu cases in Azerbaijan to eight, five of which were fatal.

Bird flu has so far killed 109 people and led to the death and culling of some 200 million birds since late 2003.

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.184.152 von [KERN]Codex am 12.04.06 22:26:30

[mikel_ann]

Antwort auf Beitrag Nr.: 21.184.364 von [KERN]Codex am 12.04.06 22:41:55

[kafutznik]

<<rechne damit das wir bis 6 Dollar laufen ohne News alles bestens warum auch nicht hat sich fundamental nichts geändert und der chef kauft nicht für 130000 Dollar Aktien wenn er nicht etwas wüste das ist fakt der will auch geld verdienen ihr werdet sehen einmalige gelegenheit günstig einzukaufen nur meine meinung

[idon]

Mojn mojn,

absolut deiner Meinung, und um die 6 USD wieder zu knacken wird es sicher wieder etwas Geplänkel geben, wenn es nicht wieder gute News gibt, denn dann wird es sehr sehr schnell in höhere Zahlen gehen.

ich bin der gleichen Meinung wie whyso, Füsse untern Tisch und laufen lassen

wünsche euch und NVAX nen schönen Tag, Idon

[AidanQ.]

...denke auch. das war eine konsolidierung der übertriebenen art (was volumen und geschwindigkeit angeht). wenn alle, die schnell raus sind auch wieder rein wollen, stehen wir am monatsende wieder bei 8$. außerdem stehen news der letzten conferenz noch an. gestern wurden zum schluss nochmal über 500k gekauft. da bekommen bald einige kalte füße. ich persön. hatte mit einer techn. reaktion gerechnet.aber das war wohl keine. irgendwie hat mir der analyst einen bärendienst erwiesen. habe jetzt 2500 shares mehr im depot ohne einen cent dazubezahlt haben zu müssen

[bubu]

Vorbörse USA: 5,42 x 5,51 USD, Last: 5,45
Schlusskurs gestern: 5,46

Mich wundert ja, daß die quasi umsatzlose Vorbörse nicht deutlich fester ist, freue mich aber trotzdem über den Turnaround gestern und hoffe, daß er noch nicht zuende ist.

Gruß
bubu

[hemj79]

und weiter gehts richtung norden 5,6$

[bubu]

5,60 USD

Frankfurt 4,58 x 4,65!

[bubu]

Kurze (?) Verschnaufpause bei 5,60
Dayhigh 5,69

Würde mich auf den Bereich 6,00 - 6,20 oder Gapschluß bei ca. 6,50 freuen.

Gruß
bubu

[AidanQ.]

..auf jeden fall ist die kehrtwende erstmal eingeläutet

[bubu]

Antwort auf Beitrag Nr.: 21.193.722 von bubu am 13.04.06 16:02:32

Nächster Anlauf:

5,68 x 5,69

Kaum Umsatz in D

[AidanQ.]

...schade, etwas enttäuschend zum schluss. mal sehen, wie morgen ausgeht

[AidanQ.]

...nachbörslich wieder auf 5,45$

frohe ostern

[bubu]

Mal Off Topic:

Findet in USA heute und/oder Montag Handel statt?

Danke und Gruß
bubu

[idon]

heute nicht, wirst du gemerkt haben, Montag ja

Gruss, Idon

[idon]

es wird agiert, mal gespannt, wie es sich auf NVAX auswirken wird

Fuente: © World Bank
http://www.worldbank.org

G8 To Boost Funding For Vaccines


/noticias.info/ “At their upcoming meeting in April in Washington, DC, finance ministers from the Group of Eight (G8) industrialized nations are expected to approve an advanced market commitment (AMC) plan to provide between $800 million and $6 billion to subsidize the purchase of new vaccines for some of the world’s most prevalent infectious disease,” writes The Lancet (UK).

“Under the plan, wealthy nations will provide funding to pharmaceutical companies to allow production of safe and effective vaccines that can then be sold at reduced prices in developing countries. According to Amie Batson, Senior Health Specialist at the World Bank Human Development Network, the Bank and the Global Alliance for Vaccines and Immunization have been asked by the G8 to do the necessary analysis and convene experts and stakeholders to gather their recommendations on the AMC pilot and the choice of vaccine.

An independent expert committee met on Feb 26 – 27 to evaluate and prioritize the six candidate vaccine-preventable, or potentially preventable, diseases: HIV/ AIDS, tuberculosis, malaria, human papillomavirus, pneumooccus, and rotavirus. Batson adds, ‘The G8 and the rest of the development community are looking to AMCs to make significant inroads into preventing diseases that routinely kill millions of children and adults every year. We hope to hear an announcement on the inaugural vaccine choice in late April when the G8 finance ministers meet.’(…)”

Greets, Idon

[idon]

Antwort auf Beitrag Nr.: 21.204.332 von idon am 14.04.06 20:51:03

Dieses Treffen der G8 ist am 21/04/06

[idon]

Antwort auf Beitrag Nr.: 21.204.344 von idon am 14.04.06 20:53:28

ziemlich heftige Story, lesenswert und macht nachdenklich

http://www.ketv.com/health/8693560/detail.html

[whyso]

Watch "the Map" get smaller and watch "the Stock" grow accordingly...



http://www.pandemicflu.gov/

Das ganze steckt leider gottes m.E. noch erst in die Kinderschuhe,

Beste Grüße & UP,
Whyso (der die jüngste "dip" seit Anfang April richtig ausgenützt hat im sachen NVAX nachkauf )

[whyso]

von 3-109 Todesfälle in knapp drei Jahren!

http://www.who.int/csr/disease/avian_influenza/country/cases…

Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO

das lieber leute stellt ein erhebliche Progression dar (ob wir es mögen, oder nicht)

[whyso]

Stockconsultant, Rodman & Oppenheimer go NVAX:

Stockconsultant: http://www.stockconsultant.com/consultnow/basicplus.cgi?ID=s…

Oppenheimer:111105Oppenheimer.pdf

Rodman: 031706NVAXReview.pdf

Errinert ihr Euch warum? (-nothing has changed, aber der größere Szenario ist evtl. sogar aussichtreicher geworden )

Bis denne,
Whyso

[idon]

Hy whyso, nice to read you again, its always related to an uptrend when you're there and read this at

http://www.philly.com/mld/inquirer/business/14351170.htm


A new mode of bird-flu fightingA small Malvern drugmaker has devised a way that may make vaccine faster, cheaper and more potent.
By Linda Loyd
Inquirer Staff Writer
Rick Bright and his former colleagues at the Centers for Disease Control and Prevention have seen many companies jump on the avian-flu bandwagon, with a slew of potential treatments if a pandemic breaks out.

"I've heard so many things, so many wild ideas. I've seen it all," said Bright, a virologist and immunologist at the CDC's influenza branch for nine years.

But it is a small Malvern company, called Novavax Inc., that Bright says may have a viable solution to bird flu. The researcher recently left the CDC to take the helm of Novavax's vaccine research.

Drugmakers are racing to come up with new approaches to bird flu, as the lethal H5N1 strain has killed millions of birds and spread from Asia to Europe, Africa and the Middle East, killing more than 100 people. The virus is not yet transmissible among people.

Just eight months ago, Novavax had a money-losing estrogen lotion and shares trading at less than $1. But the drugmaker has had a remarkable change of fortune. For that it can thank avian-flu fears and a technology that may hold the promise of making an avian-flu vaccine faster, cheaper and more potent than conventional influenza vaccines.

"We are very excited about Novavax's approach," said Terry Tumpey, senior microbiologist at the CDC, which is working with more than a dozen smaller companies on new technologies to narrow the time it takes to make an avian-influenza vaccine.

Novavax has a different way of making flu vaccine, using virus-like-particle technology (VLP) that extracts protein genes from influenza virus and turns them into particles that mimic the virus and trick the immune system into creating antibodies.

The recombinant particles can be customized into a vaccine in about two to three months, instead of the six to nine months it takes to create a conventional flu vaccine in chicken eggs.

Other companies are developing VLP vaccines for AIDS, severe acute respiratory syndrome (SARS), and human papilloma virus. But no other company is using the technology for flu, and Novavax has pending patents, said president and chief executive officer Rahul Singhvi.

Since 2001, Novavax scientists have been working on an avian-flu vaccine with the CDC, using a grant of about $1 million from the National Institutes of Health.

In August, when preclinical results were published in the online edition of the journal Vaccine, Wall Street investors noticed. The stock rose from 87 cents Aug. 15 to $7.98 March 31, hitting a 52-week high of $8.31 March 20.

The study reported strong immune protection in mice at low doses against the H9N2 strain, which first appeared in Hong Kong in 1998, without adding immune-boosting chemicals. Novavax plans to test the vaccine this fall in human clinical trials.

The company is in the process of making a vaccine against H5N1, the strain that worries health experts the most. The CDC is preparing to test the H5N1 vaccine in animals.

Novavax's VLP vaccine has "a lot of potential" because it can be made quickly and will be "cost-effective" since the company intends to use a portable manufacturing process, said the CDC's Tumpey.

Flu manufacturers now make vaccines in stainless-steel tanks in multimillion-dollar plants. Novavax plans to use disposable equipment, which can be "scaled up" to make large quantities in case of a pandemic.

The company is collaborating with Wave Biotech L.L.C., of Somerset, N.J., to develop a commercial-scale production process. Manufacturing will be in sterile medical-grade plastic bags, using disposable cartridges and filters that can be thrown away and incinerated after each batch.

The portable manufacturing could go into any "clean room" in the world where there is electricity. "We did an experiment and found it worked beautifully," said Singhvi, a chemical engineer from the Massachusetts Institute of Technology who spent 10 years in vaccine development and manufacturing at Merck & Co. Inc.

"No other vaccine manufacturer in flu is using this approach yet," said Bright, who worked with avian influenza at the CDC from 1997 until February.

Novavax's product probably will not be approved for mass distribution until 2008, but potentially could be ready in winter 2007 if there were a pandemic, Singhvi said.

•

Only eight months ago, the company's prospects looked dim. The stock hit a year low Aug. 10 of 74 cents.

When Singhvi became CEO on Aug. 9, Novavax had about $5 million in cash and was carrying $35 million in debt. Sales of its Estrasorb estrogen lotion were tepid, and the company was losing $2 million to $2.5 million a month.

In his first act as CEO, Singhvi fired the sales and marketing staff of 40 to 45, shrinking the company by half. Today, Novavax employs 52 full-time and five part-time employees.

A turning point came in October, when Novavax licensed rights to Estrasorb to Esprit Pharma Inc. for $12.5 million up-front, plus double-digit royalties on sales and milestone payments. In addition, Novavax continued to manufacture the product at its Northeast Philadelphia plant.

Capitalizing on investor enthusiasm and its rising stock price, Novavax raised $18 million in November through a public stock offering.

In February, the company received an additional $20 million from two Silicon Valley venture firms: Kleiner Perkins Caufield & Byers, which has backed Google Inc., AOL and Genentech Inc., and Prospect Venture Partners.

Not everyone thinks the company's avian-flu vaccine program is a panacea. Shares, which had become a trader's favorite in recent months, lost ground recently after RBC Capital Markets cut its rating on the company's stock to "underperform," saying bird-flu-vaccine expectations were overblown. Shares have fallen 19 percent since their Nasdaq close at $6.68 on April 5. Shares closed Thursday at $5.38.

"The expectations for Novavax are way ahead of the company's ability to deliver a safe, functioning vaccine that has been tested in humans with validated, commercial-scale manufacturing," RBC analyst Ken Trbovich wrote in a research note. "We believe the valuation is running so far in front of so many other small companies with a focus on flu and other vaccines that the stock has the potential for a significant sell-off when the bird-flu-scare cools."

Trbovich said in an interview that the technology was "intriguing" and "a novel approach," but that "until they have real data from their vaccine, it's almost impossible to draw conclusions."

"In the end," he said, "the new management team has done a good job in repositioning this company. But it's a long way away from ringing the cash registers."

In February, Kleiner Perkins announced a $200 million fund to invest in innovative companies working on vaccines and drugs for emerging infectious diseases, including pandemic flu.

"Time and again people said, 'You've got to go see this company Novavax,' " said Kleiner Perkins managing partner Brook Byers, who said his firm invested $12.5 million in Novavax based on the management team, which came from Merck and other companies with expertise in vaccines and in scientific technology.

"VLPs are the hot thing in vaccines now," Byers said. "Using viruslike particles, you can make a vaccine for five or 10 targets, all in the same vaccine. So the coverage of protection from the vaccine could be broad. Novavax, we believe, is one of the leaders in VLP technology."

In September 2004, Novavax moved its headquarters to Malvern from Columbia, Md., but kept its vaccines division and about 20 scientists in Rockville, Md.

With the company's recent focus on bird flu, Novavax is in talks with Maryland economic-development officials about securing incentives to expand vaccine operations in Maryland - and possibly move the headquarters back there.

"The corporate headquarters move is still up in the air," Singhvi said, "but what is definite is, we are going to a bigger facility in Maryland for our vaccine operations."

Even if the company does relocate, the Philadelphia-area operations will remain. Only "two or three" of Malvern's 15 employees will move, Singhvi said. And a 24,000-square-foot manufacturing facility that employs 20 in Northeast Philadelphia will stay open "and may expand," he said.

What happens if the dreaded global epidemic never pans out? The company is not putting all its efforts into avian flu.

"The second program we are going after is a seasonal-flu vaccine," Singhvi said. "Beyond that, we have another program in HIV vaccine that is currently being supported by NIH grants. We are planning to add more to our pipeline as we get more people."

Novavax Changes Direction

June 30: Shares of Malvern-based Novavax Inc. close at $1.32. It has $4.4 million in cash and cash equivalents and a money-losing estrogen cream, Estrasorb.

Aug. 9: Former chief executive officer Nelson Sims retires and is replaced by Rahul Singhvi, whose first move is to lay off the sales and marketing staff, cutting the workforce in half to reduce costs.

Aug. 25: Novavax reports positive preclinical results of its H9N2 avian-flu vaccine, as detailed in the journal Vaccine. Shares begin a steady move upward.

Sept. 13: Novavax announces collaboration with Wave Biotech L.L.C. to develop a process for commercial-scale production for pandemic-flu vaccine, using disposable manufacturing equipment.

Oct. 18: The company announces a licensing agreement for Estrasorb with Esprit Pharma, of East Brunswick, N.J., for $12.5 million, plus double-digit sales royalties and milestone payments.

Nov. 2: Novavax raises $18 million in a secondary stock offering, selling 4.2 million shares at $4.30 a share.

Feb. 2: Rick Bright, immunologist and virologist at the Centers for Disease Control and Prevention, joins the company as vice president of vaccine research.

Feb. 15: Novavax begins collaboration with the University of Pittsburgh School of Medicine to test its flu vaccines and a proprietary vaccine adjuvant.

Feb. 27: The company receives $20 million from two California venture-capital firms - Kleiner Perkins Caufield & Byers and Prospect Venture Partners - by selling 4.6 million shares at $4.35 per share.

Feb. 28: Novavax forms alliance with PacificGMP, of San Diego, to manufacture large quantities of avian-flu vaccine.

March 6: Novavax and Bharat Biotech International Ltd. announce alliance to develop pandemic-influenza vaccine for India and other south Asian countries.

March 20: Shares reach a 52-week high of $8.31.

March 21: Company sells 5.2 million shares of common stock at $7.30 a share, raising $36.1 million.

March 31: Holders of Novavax convertible notes choose to convert $7 million in notes to 1.3 million shares of common stock at a price of $5.46 a share.

April 13: Shares close at $5.38.

Fighting Flu on Many Fronts

Amid fear of an avian-flu outbreak in humans, many firms are developing therapeutics, antivirals and vaccines. Here are what several in the Philadelphia area are doing:

Sanofi Pasteur of Swiftwater, Pa., has a $100 million contract to supply experimental H5N1 avian-flu vaccine to a U.S. government stockpile. In 2004, Sanofi began supplying the U.S. government with two million vaccine doses. In addition, the French-based drugmaker is under contract to provide a year-round supply of chicken eggs for U.S. vaccine production, and is working on a new cell-culture influenza vaccine.

GlaxoSmithKline P.L.C. has begun human testing of two vaccines against the H5N1 strain, with the aim of having a vaccine in production before the end of the year. With a U.S. headquarters in Philadelphia, GlaxoSmithKline has committed $2 billion to expand manufacturing capacity for seasonal-flu vaccine and its antiviral drug, Relenza. The company has submitted an application to European regulators for a pandemic vaccine for strains H2N2 and H9N2. GlaxoSmithKline also acquired Canadian vaccine-maker ID Biomedical Corp. for $1.4 billion.

Hemispherx Biopharma Inc. of Philadelphia said lab tests showed that its immune-system drugs Ampligen and Alferon might strengthen the power of current treatments against avian influenza. The company said its experimental Ampligen drug boosted effectiveness of Roche Holding AG's Tamiflu and GlaxoSmithKline's Relenza antivirals in lab testing and in mice. An oral form of Alferon, tested in healthy humans, may stimulate genes that play a role in building the body's defense system. Alferon is approved as an injectable treatment for genital warts.

Quigley Pharma of Doylestown announced plans to test its antiviral compound QR-441A against the H5N1 virus in poultry.

Elsewhere, companies working on avian-flu treatments include: Chiron Corp., Emeryville, Calif.; BioCryst Pharmaceuticals, Birmingham, Ala.; Alnylam Pharmaceuticals, Cambridge, Mass.; Generex Biotechnology Corp., Toronto; AVI Biopharma Inc., Portland, Ore.; Peregrine Pharmaceuticals Inc., Tustin, Calif.; and MultiCell Technologies Inc., Lincoln, R.I.


--------------------------------------------------------------------------------


frohe Ostern und Mist, dass Frankfurt morgen geschlossen ist

[hemj79]

Novavax Successfully Completes Additional Vaccine Milestone
Monday April 17, 7:00 am ET
- Validation of cGMP Biological Manufacturing Facility Complete -

MALVERN, Pa., April 17 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) announced today that it has successfully completed the renovation and validation for current "Good Manufacturing Practices" (cGMP) compliance of it's industrial facility located in Rockville, Maryland. This validation will allow production of clinical grade materials of its virus-like particle (VLP) vaccine candidates against H5N1 and other pandemic influenza as well as for human seasonal influenza. The facility, located at One Taft Court, Rockville, Maryland, was released for manufacture of biological products in compliance with current U.S. Food and Drug Administration (FDA) standards by a leading independent consulting firm.

ADVERTISEMENT
Commenting on this additional milestone achievement, Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax stated, "This is an important event in our overall plan to evaluate our VLP pandemic influenza vaccine candidate in human clinical trials anticipated later this year. The completion of this goal, which was achieved ahead of schedule, is a testament to the dedication and hard work of the many employees at Novavax that participated in this significant effort. We are now in a position to take advantage of the FDA Draft Guidance on clinical data that would support accelerated approval of pandemic influenza vaccines. The FDA has recently provided guidance on the surrogate markers of efficacy and the safety data required to support an accelerated approval for licensing of a pandemic influenza vaccine. The guidance applies not only to currently licensed vaccines where an indication is sought for pandemic influenza, but also to vaccines that are not currently licensed. This Guidance will be the roadmap for our clinical development plans."

More information on the FDA's Draft "Guidance to the Industry: Clinical Data to Support the Licensure of Pandemic Influenza Vaccines" issued March 2006 for comment can be obtained at the FDA Web site: http://www.fda.gov/cber/gdlns/panfluvac.pdf .

"To validate a facility compliant with current GMP standards is a difficult and challenging hurdle and can become a rate-limiting step in the development of vaccines. We are delighted to have initiated the cGMP manufacture of VLP influenza vaccines well ahead of schedule. With a validated cGMP production capability now in-house, we can produce the requisite clinical trial materials in an efficient and timely manner to support the human testing planned of our pandemic and seasonal influenza vaccine programs. Clinical manufacturing at our Rockville facility will allow us to now complement the preparation work being conducted at our partner's PacificGMP's facility located in San Diego, California," stated Dr. Gale Smith, Vice President of Vaccine Development at Novavax.

[bubu]

Vorbörse 5,74 USD
Damit wären wir nahe Tageshoch vom Donnerstag und satte 36ct im Plus relativ zum Schlußkurs.

Gruß
bubu

[AidanQ.]

hi leuts, hi whyso...wo finde ich die pdf's von oppen.und rod.
greets aidan

[whyso]

Antwort auf Beitrag Nr.: 21.212.513 von AidanQ. am 17.04.06 14:24:40

Hi Aidan, auf die jeweilige Rodman & Oppenheimer websites!

Leute wilkommen in der "-JETZT VERDIENEN WIR GELD - Phase des NVAX Entwicklung...

http://biz.yahoo.com/ap/060417/novavax_plant.html?.v=1

http://biz.yahoo.com/prnews/060417/nym080.html?.v=32

Nun heisst es, all the way back to 8-dann 10, und erst DANN gehts richtig los!


Übrigens; Pre-Market (RT-ECN): 5.70 0.32 (5.95%)

Die Woche sollte spannend werden(zumindest für die shorties )

So & jetzt ab zum Fussball Platz mit mein Söhnemann-bis später!
Whyso

[AidanQ.]

...osterhandel in den usa, schwache umsätze, in denen die news noch nicht verarbeitet sind. ab morgen wieder mit voller kraft

[[KERN]Codex]

ACHTUNG WERBUNG

http://www.brn-ag.de/realplayer.php4?ident=8188

[Vinyard]

Würdet ihr nochmal nachlegen?

[whyso]

Antwort auf Beitrag Nr.: 21.218.346 von [KERN]Codex am 17.04.06 23:06:29

@Kern, das war etwas "billig"...

Ein solche "Aktion" hat weder NVAX noch MGN nötig...

Eine schöne Restwoche wünscht dir/Euch/uns,
Whyso

[idon]

!!!! Positive News, es geht weiter !!!!

AP
Novavax Upgrades Rockville Plant
Monday April 17, 8:05 am ET
Novavax Upgrades Rockville Plant According to FDA Guidelines to Make Flu Vaccines


MALVERN, Pa. (AP) -- Novavax Inc., a maker of drugs and drug delivery technology, said Monday it finished bringing its Rockville, Md.-based plant up to code to make bird flu vaccines.
The company said it renovated and validated the facility according to good manufacturing practices as outlined in recently released guidance from the Food and Drug Administration.

Novavax said it is using the FDA guidance as "roadmap" for its clinical development plans of vaccines for the H5N1 bird flu strain as well as other flu strains.

"This is an important event in our overall plan to evaluate our VLP pandemic influenza vaccine candidate in human clinical trials anticipated later this year," said Rahul Singhvi, president and chief executive, in a statement. The company said it completed the renovation ahead of schedule.

The upgrade of the Rockville plant will allow Novavax to complement the preparation of vaccines with its partner PacificGMP LLC in San Diego, the company said.



Idon

[AidanQ.]

...kaum umsatz in der vorbörse

[AidanQ.]

...seltsamer kursverlauf heute. mehr verkäufer als käufer und trotzdem steigende kurse. da wird anscheinend alles aufgesogen.aber verdächtig kleiner umsatz.

[AidanQ.]

..gleiche spiel wie gestern

[AidanQ.]

...super news, kaum umsatz, die nasdag macht 4% in 2 tagen und nvax dümpelt vor sich hin. hat jemand eine erklärung?

[whyso]

Antwort auf Beitrag Nr.: 21.244.872 von AidanQ. am 19.04.06 20:15:58

@AIDAN, mach dich selbst nicht verrückt...

Lass NVAX ein paar wochen einfach so im Markt treiben (diese Ruhephasen nach negativen Presse http://www.forbes.com/2006/04/07/novavax-chiron-0407markets1… werden die Aktie LANGFRISTIG sehr gut tun

Der Tagesverlauf heute (und fast jeden Tag bei schwäche) spricht bände, erst leicht fallend und dann werden die Teile wieder ins Nest geholt kurz vor Schluss.

Ein Schelm wer böses dabei denkt

Machs gut & bis die Tage in ganz andere Höhenregionen befindlich,
Whyso

[AidanQ.]

..eigentlich hast du recht, gute nacht

[idon]

Flight from Singapore isol. in DK
by: novavax (39/M/Denmark)
Long-Term Sentiment: Strong Buy 04/20/06 03:09 am
Msg: 212352 of 212352

Fear of human with BF

Hole airplane isolated.

Breaking news - Denmark

http://www.borsen.dk/650.87524?rss

jetzt könnte es spannend werden, sehr spannend !!!!

greets, Idon

[idon]

Da hat wohl einer Glück gehabt!!! Schade für NVAX

Re: Flight from Singapore isol. in DK
by: novavax (39/M/Denmark)
Long-Term Sentiment: Strong Buy 04/20/06 03:50 am
Msg: 212354 of 212354

Wild goose :-) lucky for this person!

Fear of bird flu in Kastrup Airport was stomach trouble

http://www.borsen.dk/650.87529?rss

The authorities isolated Thursday morning an aircraft at Kastrup airport for fear that a passenger could be infected by bird flu. The alarm was soon after cancelled when the police said that an examination had proved it was only stomach trouble. The aircraft arriving from Singapore had just landed when a passenger felt sick.

[kafutznik]

NOVAVAX INC Quick Quote: NVAX 5.48 (Even)




Novavax to Present at UBS Global Specialty Pharmaceuticals Conference
4/20/2006

MALVERN, Pa., April 20, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Novavax, Inc. (Nasdaq: NVAX), today announced that Dr. Rahul Singhvi, President and Chief Executive Officer, is scheduled to present at UBS Global Specialty Pharmaceuticals Conference on Monday April 24, 2006 at 12:00 p.m. EDT at the Grand Hyatt New York in New York City. Dr. Singhvi will update the investment community on the progress that the Company is making on accomplishing its stated goal and objectives.

The presentation will be available via a live audio webcast that may be accessed under the Conferences icon and following the link for webcast next to the Global Specialty Pharmaceuticals Conference heading at http://www.ibb.ubs.com/. The presentation will be archived for 30 days. Additional information regarding Novavax can be found at http://www.Novavax.com.

About Novavax, Inc.

Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.

Forward Looking Statements

Statements made in this press release that state Novavax's or management's intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners, competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to establish and maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10K for the year ended December 31, 2005 incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel [phone] or the SEC at www.sec.gov.

SOURCE Novavax, Inc.

Kathy Hamilton, Investor Relations for Novavax Inc., [phone], [e-mail] http://www.prnewswire.com

Copyright (C) 2006 PR Newswire

[hemj79]

hey,

hat jemand einen Grund für die -5,66% in Frankfurt?

[AidanQ.]

..der deutsche markt hat hier nix zu sagen, ob -5% oder -10%. kurs ist eh unter pari.
bollinger noch verdammt weit auseinander, die geringen umsätze werden den kurs wohl noch etwas drücken.
am montag dann conferenz, die newspipeline dürfte wieder gefüllt werden. so, werde nun das gute wetter genießen und meine persönliche golfsaison eröffnen.

ps. der trendsport in diesem jahr uphillgolf

www.uphillgolf.de

[AidanQ.]

...up, gerade im moment der kurs auf 4,32€, also, geht doch

[whyso]

Antwort auf Beitrag Nr.: 21.270.730 von AidanQ. am 21.04.06 13:39:48

...genau richtig Aidan

Ein schönes Wochenende wünscht dir,
Whyso

[e.1]

dafür legt cbmx jetzt mal was zu.
nvax ist noch zurückhalten. leider nur einen kurzen anlauf genommen.

hoffe auf bessere kurse.

gruß
e.1

[AidanQ.]

...coole schlussauktion. wenn da mal nächste woche keine fetten kommen.

...ebenfalls sonniges wochenende wünscht aidan

[e.1]

hallo,

kann jemand was zur charttechnik dagen, wie es da aussieht.
vielleicht kommen da ein paar sonnenstrahlen auf was den kursverlauf betrifft.

[AidanQ.]

...in einer stunde gehts los, mal sehen, was der tag bringt.

MALVERN, Pa., April 20 /PRNewswire-FirstCall/ -- Novavax, Inc. , today announced that Dr. Rahul Singhvi, President and Chief Executive Officer, is scheduled to present at UBS Global Specialty Pharmaceuticals Conference on Monday April 24, 2006 at 12:00 p.m. EDT at the Grand Hyatt New York in New York City. Dr. Singhvi will update the investment community on the progress that the Company is making on accomplishing its stated goal and objectives.

[AidanQ.]

...gibt es schon news von gestern

[AidanQ.]

..heute scheint ja etwas käuferinteresse zu sein. einige schöne pakete sind schon über den tisch gegangen

[AidanQ.]

...also im yahoo board ist mehr stimmung

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

[e.1]

wie weit geht es denn noch? ist bei 5$ wenigstens der abschlag wieder vorbei.
ich hoffe, daß ich recht behalten.

gruß
e.1

[whyso]

Leute denkt dran welche Instis hier schonmal gekauft haben(Merrill, Rodman & Renshaw & Oppenheimer) - sie sind alle immer noch dabei

Denk auch an die verschiedene zukäufe des CEO's ...wenn es wieder "Tief genug" ist, werden die jungs NVAX wieder auf der überholspür führen, aber dann so schnell, das gar kein shortie die Zeit haben wird um mitzuhalten bzw umzuschalten.

Diese "Bereinigung" nehme ich jedenfalls im Kauf;

Viele Grüße @alle,
Whyso

[AidanQ.]

...die 100 ma hält bestimmt. dann sollte das tief auch bestätigt sein


..habe heute im yahooboard einen guten satz gelesen.

life is short, eat desert first..in diesem sinne gute nacht all

[whyso]

@e.1---BM -

[AidanQ.]

...hier noch ein interessanter link

http://library.corporate-ir.net/library/71/711/71178/items/1…

[AidanQ.]

...wieder abgeprallt

[Glück]

Antwort auf Beitrag Nr.: 21.339.391 von whyso am 27.04.06 08:16:02

BM und ich?

Bin vor ein paar Tagen ausgestiegen...hatte mit
NVAX aber nur bedingt etwas zu tun. Möchte meinen
Gesamtaktienbestand über den Sommer etwas reduzueren

Good Luck

[e.1]

hat auch heute gehalten die 5$. ich hoffe, dass das jetzt mal das Signal war, um wieder höhere kurse zu sehen.

noch einen schönen abend

e.1

[[KERN]Codex]

hey leute,

schaut euch nochmal mologens news an, bitte

das könnte dieses jahr echt was werden

gruß aus hamburg,

birdflu rockt im moment nicht

[AidanQ.]

...vorbörse supi, gute stimmung auch im us board...bis jetzt

[AidanQ.]

http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

[AidanQ.]

http://www.marketwatch.com/News/Story/Story.aspx?guid=%7BA39…

[AidanQ.]

Novavax Board Elects Dr. James B. Tananbaum as Director


2006-04-28 09:47 ET - News Release


MALVERN, Pa., April 28 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced that its board of directors has elected James B. Tananbaum, M.D., as a director, effective immediately. Dr. Tananbaum is managing director of Prospect Venture Partners, a venture capital firm based in Palo Alto, Calif.

Prospect Venture Partners III recently accumulated a substantial stock equity position in Novavax through a combination of open market purchases and a direct placement from the company.

On behalf of the Novavax Board of Directors, Chairman Gary C. Evans, said, "We are very excited about our new business relationship with Jim Tananbaum and his colleagues at Prospect Venture Partners. Their reputation and track record in our industry is outstanding, and Jim's interest and investment in Novavax is strong validation of our vaccine development strategy.

"We plan on fully utilizing Dr. Tananbaum's knowledge, experience and associations in assisting the Novavax management team as we further develop and capitalize on our unique technology."

"I am extremely pleased to join the Novavax board and to work closely with a company that has the potential to have a significant impact on public health around the world," Dr. Tananbaum said. "The Prospect Venture Partners team believes that Novavax's unique approach to creating vaccines that tackle various strains of flu could one day save countless lives."

Dr. Tananbaum has substantial experience in identifying and nurturing high-potential health care companies. Over the last decade, Dr. Tananbaum has helped found or led financings for numerous biotechnology, pharmaceutical and healthcare service companies, including Infinity Pharmaceuticals, Jazz Pharmaceuticals, PatientCare, Predicant, CompHealth, Nanosys, Vanda Pharmaceuticals and Vitae Pharmaceuticals. Previously, as a partner at Sierra Ventures, Dr. Tananbaum led investments in Amerigroup, Healtheon, Intensiva HealthCare Corp. and NovaMed EyeCare Management.

A graduate of Yale University, Dr. Tananbaum earned his medical degree and M.B.A. at Harvard University. While still at school, Dr. Tananbaum co-founded GelTex Pharmaceuticals, which was purchased by Genzyme for $1.6 billion. Dr. Tananbaum also co-founded Theravance in 1997. Serving as chief executive of Theravance, which is now publicly traded, Dr. Tananbaum raised $300 million and hired more than 200 employees. Dr. Tananbaum began his career at Merck & Co. as a product manager.

Dr. Tananbaum is a member of the Young Presidents' Organization and an officer of the Golden Gate Chapter, as well as a member of the Harvard/MIT Health Sciences and Technology Visiting Committee.

About Novavax, Inc.

Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.

Forward-Looking Statements

Statements made in this press release that state Novavax's or its management's intentions, hopes, beliefs, expectations, or predictions are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners; competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10-K for the year ended December 31, 2004 and quarterly reports on Form 10-Q for the quarters ended March 31, 2005, June 30, 2005 and September 30, 2005, incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355, Tel: [phone] or the SEC at http://www.sec.gov.

Novavax, Inc.

[radic]

schöner rebound,

von 5 nach oben kräftig abgeprallt,

war's das?


well' see , long

[mikel_ann]

Schönes Wochenende mit +6,5%

[whyso]

Alles weiterhin im Butter (bis auf die 15 Tagestrend)-und der rückt bald nach





Moving Average Indicators
15 Day Trend (n)
45 Day Trend (p)
100 Day Trend (p)

Ich sehe hier kein Grund warum man gehen soll aber viele Gründe wieso man hier gut verweilen kann z.Bsp dieses http://www.stockhouse.com/news/news.asp?newsid=3564710&tick=…

In for the long run -(mindestens 15$ plus)-,
Whyso

[AidanQ.]

..der kurs sagt das gleiche

[AidanQ.]

...auch gut

http://www.stockwatch.com/swnet/newsit/newsit_newsit.aspx?bi…

[e.1]

wieso geht es denn heute wieder so zurück. eigentlich dachte ich, dass es jetzt zumindest bis zur 7$ hochgeht.

[AidanQ.]

Antwort auf Beitrag Nr.: 21.409.347 von e.1 am 02.05.06 21:39:18

cry:http://www.politicalgateway.com/news/read/10924

[AidanQ.]

...partytime

[kafutznik]

Der schießt durch die decke

[e.1]

na ja, hat sich ja schon wieder um 5% beruhigt

wäre schön, wenn es nochmal raufgehen würde.

[AidanQ.]

...was bedeutet das für nvax

http://www.hhs.gov/news/press/2006pres/20060504.html

[mikel_ann]

SK 6$, es kann losgehen !

[stef12]

jedenfalls ist Novavax nicht dabei.
warum steigt der Kurs???

[powerchord]

Ich denke, daß Novavax als Partner für einen der ganz großen Firmen unter denen jetzt die 1 Billion Dollars verteilt wird potentiell in Frage kommt, da die Technologie von NVAX schon sehr weit und ausgereift ist. Außerdem ist die Pipeline unserer NVAX pampevoll mit anderen nicht birdflu betreffenden Produkten. Mein persönliches Kursziel:10-15 USD für 2006. Also mich würde ein Joint Venture mit einem weltweiten Bigplayer in Sachen Birdflu nicht überraschen. Und was dann mit dem Kurs passieren würde, könnte sich wohl jeder hier vorstellen.....

[powerchord]

Antwort auf Beitrag Nr.: 21.438.535 von stef12 am 05.05.06 00:37:28

Ich denke, daß Novavax als Partner für einen der ganz großen Firmen unter denen jetzt die 1 Billion Dollars verteilt wird potentiell in Frage kommt, da die Technologie von NVAX schon sehr weit und ausgereift ist. Außerdem ist die Pipeline unserer NVAX pampevoll mit anderen nicht birdflu betreffenden Produkten. Mein persönliches Kursziel:10-15 USD für 2006. Also mich würde ein Joint Venture mit einem weltweiten Bigplayer in Sachen Birdflu nicht überraschen. Und was dann mit dem Kurs passieren würde, könnte sich wohl jeder hier vorstellen.....

[2375]

Antwort auf Beitrag Nr.: 21.438.911 von powerchord am 05.05.06 06:59:56

Ich halte seit Juli 05 auch eine größere Position NVAX.

Eigentlich dachte ich auch, dass NVAX direkt in den US Regierungsauftrag eingebunden wird und war gestern entsprechend enttäuscht, nachdem die 5 Beteiligten gemeldet waren.

Ich habe keine Ahnung darüber, wie weit die 5 in dieser Zelltechnologie statt Eier Technologie incl. der schnellen, mengenmäßig hohen Produktion, fortgeschritten sind.

Eigentlich glaubte ich, dass Novavax hier sehr weit fortgeschritten, ja führend ist.

Also ist der Umkehrschluss eines Joint Ventures mit einem der großen Player gar nicht so weit hergeholt.

Man bedenke dabei auch, wer inzwischen alles als Kapitalgeber dabei ist!

[kafutznik]

Antwort auf Beitrag Nr.: 21.438.937 von 2375 am 05.05.06 07:15:09

Eben nur eine Meldung darüber und was dann passiert kann sich jeder ausmalen der Kurs würde um 50% steigen mindestens also warten wir mal ab vielleicht wissen ja einige schon mehr gestern 13 Millionen aktien umgesetzt das kommt nicht von ungefähr oder ??
Ich rechne damit das wir heute weitersteigende Kurse sehen und eine Meldung wäre auch nicht schlecht also wie gesagt bei diesem Volumen gestern rechne ich mit dem besten mein Ziel für 3 Monate mindestens 10 Dollar warten wir mal ab

[AidanQ.]

http://www.advfn.com/news_Novavax-Announces-Release-Date-of-…

[whyso]

Antwort auf Beitrag Nr.: 21.433.199 von AidanQ. am 04.05.06 17:55:54

...was bedeutet das für nvax

Das bedeute das die branche "sexy & in" ist, und mit "one piece of hot news" das viele hier feststellen werden auf was für ein Pulverfaß sie seit tagen, wochen (und teilweise Monaten) sitzen

Powerchord hat völlig recht, NVAX ist Birdflu, allerdings AM ÄUßERSTEN RAND...

Was ist bitteschön an diesem Chart auszusetzen????



Nur die Ruhe leute & bis die Tage auf die weitere Fahrt gen norden,
Whyso

[AidanQ.]

http://abc.go.com/movies/birdflu.html

[kafutznik]

http://phx.corporate-ir.net/phoenix.zhtml?c=71178&p=irol-sec

[powerchord]

NVAX gewinnt wieder an Fahrt: Da wird ja fleissig eingekauft!


NOVAVAX INC - NVAX
Filed: May 08, 2006 (period: April 27, 2006)

Initial statement of beneficial ownership of securities
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL


OMB Number:3235-0104

Expires:January 31, 2008

Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
TANANBAUM JAMES B 2. Date of Event Requiring Statement (Month/Day/Year)
2006-04-27 3. Issuer Name and Ticker or Trading Symbol
NOVAVAX INC (NVAX)
(Last) (First) (Middle)
C/O PROSPECT VENTURE PARTNERS , 435 TASSO STREET, SUITE 200 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director _____ 10% Owner
_____ Officer _____ Other
(give title below) (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)
PALO ALTOCA94301 6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 3,116,637 I Held by Prospect Venture Partners III, L.P.(1)

[e.1]

hat jemand eine erklärung für diesen absturz.
würde mich echt interessieren, was da los ist.

gruß e.1

[mikel_ann]

Antwort auf Beitrag Nr.: 21.512.556 von e.1 am 10.05.06 20:44:44

Ich glaube da wollte jemand günstig einkaufen.

[e.1]

mal schauen, cbmx hat auch abgegeben.
hoffentlich hast du recht. die 5$ ist ja eine ganz gute unterstützung.
dann wünsche ich mir, dass es heute wieder bergauf geht.

gruß e.1

[e.1]

kann mir mal bitte jemand erklären, ws diese gezackere bedeutet. erst erholung, jetzt weider ins minus, ich hasse es.

gruß e.1

[cgmp]

bei diesen kursen ist man ja fast in versuchung wieder nachzukaufen
bin mla gespannt wie sich das jetz entwickelt..

[e.1]

hoffentlich gen norden, habe bei 4,88$ nochmal nachgelegt. vielleicht habe ich ja glück.

gruß

e.1

[kafutznik]

NOVAVAX INC Quick Quote: NVAX 4.96 (Even)




Novavax Announces First Quarter 2006 Financial Results
5/15/2006

MALVERN, Pa., May 15, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Novavax, Inc. (Nasdaq: NVAX) today announced its first quarter 2006 operational and financial results.

Recent Significant Events at Novavax include:
-- Strengthened Balance Sheet by raising $58MM in equity capital and
converting $7MM of outstanding convertible bonds into equity
-- Attracted well-known sophisticated institutional investors including
Kleiner Perkins Caufield & Byers and Prospect Venture Partners as new
shareholders
-- Elected Dr. James B. Tananbaum as a Board of Director member of Novavax
-- Strengthened scientific vaccine development team with the appointments
of Drs. Rick Bright, Jinyou Zhang, and Niranjan Kumar
-- Made significant progress on influenza vaccine pre-clinical programs
with both antigen and adjuvant platforms
-- Responded to US Department of Health and Human Services Request for
Proposal (RFP) for advanced development of antigen sparing influenza
vaccines
-- Completed renovation and validation for current "Good Manufacturing
Practices" (cGMP) compliance of operations facility in Rockville, MD to
create capability for manufacturing clinical grade materials

Commenting on the first quarter 2006 operating results, Dr. Rahul Singhvi, President and Chief Executive Officer, stated, "We had a solid first quarter in which we made significant progress towards all of our strategic goals. We made progress with our influenza vaccine programs, consistent with our vision to create best-in-class pandemic and seasonal influenza vaccines. We raised enough capital to continue advanced stage development of both vaccines and responded to a US DHHS RFP to access government funding. We attracted strong investors and recruits to reduce our execution risk and enhanced our intellectual property estate by filing several patent applications. We remain optimistic that our work at Novavax will result in the development of next generation vaccines against emerging infectious diseases, such as the H5N1 avian influenza."

First Quarter Financial Results

Revenues for the first quarter ended March 31, 2006 totaled $1.3 million, up 35% from $1.0 million reported in the year-ago quarter. Product revenues consisting primarily of ESTRASORB(R) sales to Esprit Pharma totaled $0.7 million for the period. This compares to product sales of $0.7 million reported in the first quarter of 2005. Contract research and development revenues for the first quarter were $0.5 million, up from $0.2 million reported in the 2005 period. This increase was a result of additional commercial contract work completed at our manufacturing facility in Pennsylvania. Also included in total revenues for the first quarter was $0.1 million in royalties from Esprit Pharma on ESTRASORB(R) sales.

Cost of products sold for the three-month period were reduced to $1.2 million versus $2.0 million for the same period last year. The 2006 quarter includes $0.4 million in idle capacity costs at our manufacturing facility compared to similar costs totaling $1.5 million in the year-ago quarter. The company incurred $0.3 million in excess inventory costs over market for the first quarter, which reflects its current production costs over the sales price of ESTRASORB(R) driven by dependence of the production costs on sales volume.

Research and development costs for the first quarter increased to $2.0 million compared to $1.2 million for the three-month period a year ago. The 66% increase in R&D was primarily due to higher spending to support the development of the Company's influenza vaccines, as well as costs related to the recording of stock-based compensation in accordance with Statement of Financial Accounting Standard No. 123 (revised) Accounting for Stock-Based Compensation ("SFAS 123R").

Selling and marketing costs were significantly reduced during the first quarter to $38 thousand from $4.1 million for the same period last year. The decrease resulted from the Company's transition from a commercial business to new product development. Novavax eliminated its sales force and marketing programs during 2005.

Total general and administrative costs were $2.7 million for the quarter, compared with $2.1 last year during the first quarter period. The increase was due to $0.6 million of costs related to the recording of stock-based compensation in accordance with SFAS 123R.

For the quarter, Novavax reported a net loss of $5.5 million, or the equivalent of 11 cents loss per share, down from an $8.9 million net loss or the equivalent of 22 cents loss per share in the year-ago period.

As of March 31, 2006, Novavax had $83.9 million in cash and cash-equivalents compared to $31.9 million at December 31, 2005, for an increase of $52.0 million. The Company received net proceeds of $20.0 million and $36.1 million from equity offerings in February and March, respectively. Both offerings were issued pursuant to existing shelf registration statements.

Conference Call

The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. EDT on May 15, 2006. The call will be hosted by Mr. Gary C. Evans, Chairman of the Board and Dr. Rahul Singhvi, President and CEO of Novavax. Other participants on the call will include senior management of Novavax. A question and answer session will follow the financial results overview. The dial in number for the conference call is 1-800-599-9795 (International 1-617-786-2905), pass code 23869726.

A live audio webcast of the conference call will be available through http://www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days starting on May 15, 2006 at http://www.novavax.com. A replay of the conference call will also be available by telephone starting on May 15, 2006 at 12:00 noon through May 22, 2006. To access the replay, dial [phone] and enter pass code 18031915 followed by the number sign.

About Novavax, Inc.

Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.

Novavax, Inc.
Consolidated Statements of Operations
(in thousands, except share and per share information)

Unaudited
Three-months ended
March 31, March 31,
2006 2005

Revenues:
Net product sales $719 $719
Contract research and development 474 243
Royalties, milestone and licensing fees 110 -
Total revenues 1,303 962

Operating costs and expenses:
Cost of products sold 1,233 1,979
Excess inventory costs over market 315 -
Research and development 2,032 1,222
Selling and administrative 38 4,057
General and administrative 2,720 2,121
Total operating costs and expenses 6,338 9,379

Loss from operations (5,035) (8,417)

Interest expense, net (460) (469)

Net loss $(5,495) $(8,886)

Basic and diluted loss per share $(0.11) $(0.22)

Basic and diluted weighted average
number of common shares outstanding 52,267,386 39,553,876



Selected Balance Sheet Data
(in thousands)

Unaudited
As of As of
March 30, December 31,
2006 2005

Cash and cash equivalents $83,941 $31,893
Total current assets $89,450 $37,611
Working capital $85,907 $32,735
Total assets $135,432 $84,382
Long term obligations $22,784 $29,854
Stockholders' equity $109,105 $49,652


Forward Looking Statements

Statements made in this press release that state Novavax's or management's intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners; competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to establish and maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10K for the year ended December 31, 2005 incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel [phone] or the SEC at www.sec.gov.

SOURCE Novavax, Inc.

Cheryl Marley of Novavax, Inc., [phone], [e-mail] http://www.prnewswire.com

Copyright (C) 2006 PR Newswire. All rights reserved

[radic]

nicht schlecht

[cgmp]

netter deal, mein nachkauf nach dem posting gestern hat mir damit schon 6,5% inkl gebühren etc eingebracht, es macht sich also bezahlt bei geringem interesse zu ordern und auf kollege bollinger zu hören

[spontanix]

gab es in der letzten zeit infos zu phase 3 des hepatitis e virus impfstoffes?war lange ned hier und hab keine zeit alles nachzulesen
bzw in wie weit ist er im aktuellen kurs inbegriffen?
denke das ist ein schönes gebiet das da abgedeckt werden kann:
http://www.netdoktor.de/krankheiten/reisemedizin/hepatitis_e…

[e.1]

10% abschlag, so hatte ich mir das nicht vorgestellt.

ich hoffe morgen wieder auf eine erholung

gruß e.1

[nort.]

[e.1]

hallo,
hat jemand z.b. infos weshalb es gestern so abwärts ging.
auch von der charttechnik her wäre es schön wenn jemand dazu etwas sagen könnte, ob ich damit richtig liege, daß es bis 4$ runtergehen kann.
oder wurde versucht billig einzusammeln.

gruß
e.1

[e.1]

ich könnte mal etwas moralischen aufbau gebrauchen, bei diesem kursrückgang, sch...

[whyso]

Antwort auf Beitrag Nr.: 21.629.430 von e.1 am 17.05.06 21:25:20

Na denn...schau dir den gesamtmarkt an Z.Zt , und der schlussspurt von NVAX in ein äußerts negativen Umfeld



moving average is $4.40. Guess where we found support today? Yup...$4.40. NVAX goes up from here. I can guarantee it. I will stake more money on it. I will add to my traders tomorrow morning premarket IF I can get them for $4.40...

GN8 Morgen(Heute) ist ein andere Tag...

[e.1]

vielen dank, kann ich echt gut gebrauchen.

schönen tag noch, trotz regen.

gruß
e.1

[AidanQ.]

..charttechnisch könnte es bis 4$ runter gehen. aber p&k haben glaube ich bei 4,35$ gekauft

[derwolf1]

19.05.2006 12:01
Novavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder

MALVERN, Pa., May 19 /PRNewswire-FirstCall/ -- Novavax, (Nachrichten) Inc. , today announced that it has entered into a definitive agreement with Esprit (Nachrichten) Pharma to co-develop, supply and commercialize Novavax's(TM) micellar nanoparticle testosterone medicine currently in development to treat female hypoactive sexual desire disorder (HSDD).

Women who suffer from HSDD have low sexual desire. Approximately 25% of women in the United States are estimated to be affected by this condition. Novavax's testosterone medicine, which applied as a lotion, is currently in Phase II clinical development.....

............www.finanznachrichten.de

Endlich Viagra für die Frau, bin schon wieder spitz wie
Nachbars Lumpi....

Noch mehr Sex und dabei n´Haufen Kohle verdienen was will
man mehr

[cgmp]

bin mal gespannt wie die amis darauf reagieren die prüden die
hm hat hier wohl noch niemand gelesen die news??
bei den stückzahlen aber schon 8cent zugelegt intraday

[mikel_ann]

Antwort auf Beitrag Nr.: 21.666.867 von cgmp am 19.05.06 13:28:37

Naja Begeisterung kam da noch wenig auf, aber immerhin
gings am Schluss etwas zur Sache.

Schönes WE

[spontanix]

hach was waren das für zeiten als man sich mit popcorn vor der inetats-applikation setzen konnte und genießen wie sich der kurs sekündlich achterbahnisiert
ich hoffe dazu kommen demnächst noch mehr details ,war ja sehr übersichtliche news *g*

[spontanix]

mal alle offiziellen news dazu:

#1

ovavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder

Esprit Receives North American Marketing Rights

MALVERN, Pa., May 19 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that it has entered into a definitive agreement with Esprit Pharma to co-develop, supply and commercialize Novavax's(TM) micellar nanoparticle testosterone medicine currently in development to treat female hypoactive sexual desire disorder (HSDD).

Women who suffer from HSDD have low sexual desire. Approximately 25% of women in the United States are estimated to be affected by this condition. Novavax's testosterone medicine, which applied as a lotion, is currently in Phase II clinical development.

Under terms of the License Agreement, Esprit will receive exclusive rights to market the product in North America. Esprit will make certain minimum payments to Novavax upon the achievement of pre-determined clinical and regulatory milestones, and royalties on all net sales of the product. The anticipated milestone and royalty payments from this new agreement will be similar in scope to our prior license agreement with Esprit executed last year. Esprit will be responsible for all development costs and will lead clinical programs. Novavax will be responsible for manufacturing the product in its existing state-of-the-art facility located in Philadelphia.

"We are delighted with our second new partnership with Esprit and believe that we have the opportunity to develop and commercialize a best-in-class product for women with HSDD," said Ray Hage, Senior Vice President and Chief Operating Officer of Novavax. "John Spitznagel and his team at Esprit have a remarkable track record of launching successful new products and this product will be a strong addition to their portfolio."

Novavax first collaborated in a business relationship with Esprit late last year when Esprit licensed Novavax's estrogen therapy lotion, ESTRASORB(R), in North America.

"We are very excited about adding this key development program to our product pipeline," said John T. Spitznagel, Esprit's Chairman and Chief Executive Officer. "Novavax's unique technology delivers testosterone through the skin in a therapeutically effective and easy-to-use lotion. This product will be very appealing to women who suffer from this condition."

Novavax President and Chief Executive Dr. Rahul Singhvi, President said the agreement "further substantiates Novavax's capabilities in product development and validates the company's novel delivery system as an important technology." The U.S. Food and Drug Administration approved ESTRASORB(R), Novavax's first lotion therapy, in 2003.

"We are confident that our novel technology will continue to enable us to develop products that have the potential to improve patient health and quality of life as well as provide unique opportunities for companies like Esprit," Dr. Singhvi said.

#2


Back to Headlines | Previous Story | Next Story
StockConsultant
Enter Symbol


NVAX: Development Agreement w/Esprit Pharma for Female Sexual Desire Treatment

Novavax Inc. (NVAX) has signed a license agreement with Esprit Pharma to develop, supply and commercialize Novavax's medicine currently in development to treat female hypoactive sexual desire disorder. The company's testosterone medicine, which is applied as a lotion, is currently in Phase II clinical development. Under the agreement, Esprit will receive exclusive rights to market the product in North America, be responsible for all development costs, and lead clinical programs.

#3

Esprit Pharma Acquires Exclusive North American Rights to a Novel Treatment for Hypoactive Sexual Desire Disorder in Women from Novavax; Sees Continuing Growing Pre-Eminence in Women's Healthcare

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--May 19, 2006--Esprit Pharma, Inc. today announced that it acquired exclusive North American rights to a novel testosterone based treatment for hypoactive sexual desire disorder (HSDD) in women. The compound is currently in phase II clinical trials in the United States. The compound is being developed as a lotion with the active ingredient encapsulated in a proprietary micellar-nanoparticle transdermal system developed by the licensor, Novavax, Inc. (NASDAQ: NVAX) of Malvern, Pa. This is Esprit's second deal with Novavax, having acquired rights to the estradiol topical emulsion ESTRASORB(R) from Novavax earlier last year.

"We are very pleased to have acquired our initial development compound in one of the areas of our current focus," said John T. Spitznagel, Esprit's Chairman & CEO. "The compound is another in Novavax Inc.'s unique technology platform. This compound will broaden our presence in the Women's Health care field," continued Mr. Spitznagel.

"Together with our SANCTURA(R), ESTRASORB(R), PROQUIN(R) XR and PROSED(R) product lines, this newly licensed compound, when launched will offer substantial opportunities to realize benefits associated with product synergies," noted Mr. Spitznagel.

Commenting on today's announcement, Greg Stokes, President & COO of Esprit, stated, "The licensing of this compound solidifies Esprit's commitment to the Women's Health Care specialty. Esprit will be responsible for the full clinical development of this compound and its ultimate marketing and promotion. We believe that this compound will be readily accepted by those women suffering from HSDD because of its elegant, user friendly dosage form."

Mr. Stokes further noted, "HSDD is an under diagnosed condition. It is anticipated that this compound when launched, will help to relieve a cause of concern in many women." Given the compound's delivery characteristics, plus the focused strength of our sales and marketing staff, backed by Esprit's dedication to medical education, we expect to realize substantial long-term growth in sales of this compound, once launched," concluded Mr. Stokes.

Dr. Rahul Singhvi, Novavax' President and CEO stated: "This important agreement substantiates Novavax' capabilities as a product development company and validates the value of the micellar nanoparticle technology (MNP) as an important FDA approved drug delivery system. We are delighted with our continuing collaboration with the Esprit Pharma management team which has a proven track record of successfully launching new products."

Financial terms of today's announced transaction were not disclosed. <--

mit einer sich erholenden börse up´náway*hoff*

[e.1]

wieso wird sie so geschlachtet? nimmt das denn gar kein ende

gruß e.1

[whyso]

Antwort auf Beitrag Nr.: 21.743.493 von e.1 am 22.05.06 18:08:37

Achte lieber auf die "upticks" immer im verlauf der späten Handel 8(überwiegend im negativen Umfeld, hier wird m.E. gezielt eingesammelt)

Ich frage mich nur wann kriegen wir die dazu angepasste "NEWS" geliefert!?!?

Ich lasse mir jedenfalls nicht "abkochen" von ein MM den ich nicht mal persönlich kenne, der 3000 Kilometer weit Entfernt irgendwo rumsitzt & sein Tagespensum im namen dritten täglich absolviert

In for the long run,
Whyso

[e.1]

ich hoffe, dass ich durchhalte.

es geht ja schon wieder aufwärts.

hoffe dass ich mein minus wieder ausbügele.

gruß e.1

[takeachance]

Hi whyso,

nachdem die Vogelgrippe ein guter Faktor war alles nach oben zu bringen haben wir jetzt Sommer, Urlaub ist allgemein angesagt.

Es bleibt die Frage wie gut ist die Pipeline? Wunder erwarte ich auch hier nicht, nvax schreibt auch noch keine schwarzen Zahlen soweit ich das gelesen habe. Deshalb gibt es auch kein meßbares KGV.

Die Engagierten setzen hier auf etwas, das mehr Zuwachs bringen könnte als GE oder IBM oder irgendetwas sonst, langfristig war nvax noch nie höher als 15, beim Doppeltop hätte ich es erst mal rauswerferen sollen. Jetzt komme ich bald wieder unter Einstand. Die Kurse spiegeln auch irgendwann die Zahlen wieder. Jetzt ist es zu spät für raus und wieder rein. Oder? Wie tief geht es noch und danach wieder rauf? Gretchenfrage. Und das Thema Sex, it sells, ok.

Ist es richtig hier zu bleiben?

Die nächsten Quartalszahlen bringen vieles weiter, aber es sollte auch bald einmal eine schwarze Null da stehen, bei aller Liebe für Pipeline.

Gruß

HSC

[kafutznik]

The Bellwether Report Takes Notice of Novavax Inc. (Nasdaq:NVAX) Novavax, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of products for women's health, infectious diseases, and cancer. Its primary product candidate, ESTRASORB, a topical emulsion for estrogen therapy is used for the treatment of vasomotor symptoms associated with menopause. The company's other products include Gynodiol, an oral estrogen replacement therapy; AVC line of products for treatment of vaginal yeast infections; Analpram HC Cream, a topical preparation for hemorrhoids; and prenatal vitamins. Novavax is also developing ANDROSORB, which is in Phase II clinical trials, a topical testosterone replacement lotion for women; two anti cancer vaccines, which are in human clinical trials for the treatment of melanoma; hepatitis vaccines in Phase III clinical trials for the prevention of hepatitis caused by the Hepatitis E virus; and E-selectin-based molecularly-derived products that are in Phase I clinical trials for the prevention of strokes. In addition, the company focuses on developing its Virus Like Particle technology into vaccines for the prevention of infectious diseases, such as pandemic and seasonal influenza, HIV-1/AIDS, and SARS. In addition, Novavax is developing E-selectin tolerogen for the prevention of inflammation leading to stroke and other diseases. It has collaborative agreements with the National Institutes of Health; National Cancer Institute; National Institute of Allergy and Infectious Disease; Walter Reed Army Institute for Research; GlaxoSmithKline Pharmaceuticals; University of Pittsburgh School of Medicine; and Wave Biotech LLC. The company has strategic alliances with Bharat Biotech International Limited and PacificGMP, LLC. It sells its products primarily in the United States and Europe. Novavax, formerly known as MPS, Inc., was founded in 1987 and is headquartered in Malvern, Pennsylvania.

Shares fell 12% upon today's announcement of the Company's CFO resigning.

BWR will continue to follow Novavax over the coming weeks as investor sentiment has changed over the past few days. We will continue to report any new corporate developments.....

To review research on Novavax Inc., as well as many more exciting articles we encourage you to visit www.bellwetherreport.com. You can find these reports under the "Today's Articles" section. No credit Card Needed!!

The Bellwether Report will continue to research the small cap markets to bring you exciting opportunities!! If you are interested in receiving more information on these small cap opportunities and other features of our site, feel free to sign up for a complimentary subscription to the #1 online investment tool www.bellwetherreport.com.

Companies looking to advertise with Bellwether Report should email [e-mail] with the subject line (Advertising).

All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.

Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

[whyso]

Antwort auf Beitrag Nr.: 21.748.111 von takeachance am 22.05.06 22:40:42

Hi takeachance (cool nick übrigens)

Bird flu is still out there, und wird als "NVAX Randprodukt" weitere Schlagzeilen machen (Tja,die Werbeschaltung ist sonst ein sehr teure Angelegenheit)

Vogelgrippe auch auf dänischem Geflügelhof

Das gefährliche Vogelgrippe-Virus H5N1 ist in einem Geflügelhof auf der dänischen Insel Fünen aufgetaucht. Nach Mitteilung der EU-Kommission in Brüssel wurde das Virus von einem dänischen Labor auf dem Hof festgestellt.

Dort werden etwa 100 Hühner, Enten, Gänse und Truthähne gehalten. Der Hof befindet sich in der selben Gegend, in der im März das H5N1-Virus in Wildvögeln nachgewiesen wurde.

Zwar seien die nach dieser Entdeckung verhängten Schutzmaßnahmen später aufgehoben worden, doch sei die Lage weiterhin intensiv beobachtet worden, erklärte die Kommission.

Deswegen habe auch das Vogelgrippe-Virus jetzt rasch entdeckt werden können. Die dänischen Behörden errichteten rund um den Geflügelhof die von der EU vorgeschriebene Schutzzone in einem Umkreis von drei Kilometern und eine Beobachtungszone im Umkreis von zehn Kilometern.

Watching & waiting,
Whyso

[Vervain]

ich wusste es doch...Novavax ist ne tolle Aktie. Hab sie schon seit Februar und mich zwiscnendurch tierisch geärgert weil ich nicht verkauft hab...
In Us nachbörslich schon 19% im Plus

[takeachance]

Hi,

nick kann ich zurückgeben.

Viagra für Frauen, mal sehen, als Viagra auf den Markt kam hat es ja auch einiges bewegt. Bleibt die Frage ob es angenommen wird vom Markt. Frauen können sehr eigen sein.

Insgesamt müßte sich NVAX aber schon ordentlich steigern in den Zahlen um richtig in die Puschen zu kommen. Das geht nicht von heute auf morgen, es tummeln sich auch noch Mitbewerber. Die alte Spitze von 15 wieder zu erobern wäre schon ein ordentliches Ziel für mich.

Es war vieles hochgeschaukelt in den letzten Wochen mangels anderer Ereignisse, der Rücksetzer in USA bringt wieder Leben in die Bude und Arbeit für die Pusher, Basher und andere Akrobaten, damit es nicht langweilig wird.

Heute ging es mal wieder nach oben , war wohl ein bißchen überverkauft alles, obwohl ich das Ende vom Gesamtmarkt nicht ganz verstehe. Eine Falle? Wird sich morgen zeigen.

Insgesamt bei mir viel grün heute. Und um ein Kursziel muß ich noch einmal ein bißchen recherchieren.

Gruß

HSC

[mikel_ann]

Antwort auf Beitrag Nr.: 21.766.054 von Vervain am 23.05.06 22:22:55

Na dann zum Ende und AH doch noch ein grünes Licht

[Vervain]

stimmt Frauen können sehr eigen sein.g. Ob das Viagra angenommen wird? Bestimmt, in einer männerdominierten Gesellschaft sind die Frauen dafür bestimmt auch offen - zwangsweise - die meisten ziehen den Männern ja immer hinterher. Und wenn Viagra den Männer geholfen hat?..dann kanns für Frauen so schlecht auch nicht sein. Oder?
...obwohl ich da eher zum Wechseln des Partners raten würde..g.

[mikel_ann]

Antwort auf Beitrag Nr.: 21.766.219 von Vervain am 23.05.06 22:30:56

AH 5.20 ... die meinen sie verpassen etwas, oder covern ganz panisch

[mikel_ann]

Antwort auf Beitrag Nr.: 21.766.219 von Vervain am 23.05.06 22:30:56

Schlecht bestimmt nicht......

Vieleicht gibt es ja bald die "Kursdroge"

[mikel_ann]

Denke hier liegt die wesntliche Ursache, die Amibolde lassen
sich arg von solchen Artikel leiten.

Why all bird flu stocks up and all rest of market down.... but here it is:



Novavax Seeing Strong Upside Momentum in Early After-Hours, Adding to Day's Gains

--------------------------------------------------------------------------------

Midnight Trader
4:30 p.m. 05/23/2006


Boston, May 23, 2006 (MidnightTrader via COMTEX) -- Novavax (NVAX), generally a volatile mover in the extended-hours, is staying true to form tonight, jumping 6% after rising a hefty 11% in today's regular session. The stock recorded the bulk of it day gains just ahead of the closing bell, likely boosted by a positive mention in a RealMoney.com commentary piece by Richard Suttmeier. Suttmeier cited the stock as a speculative biotech bargain.

Price: 4.96, Change: +0.28, Percent Change: +5.9

[whyso]

Antwort auf Beitrag Nr.: 21.766.553 von mikel_ann am 23.05.06 22:49:03

Nun das hört sich wirklich sehr "ernst" an
http://www.washingtonpost.com/wp-dyn/content/article/2006/05…

Morgen werden wir mehr in Erfahrung bringen,
Whyso

[mikel_ann]

Antwort auf Beitrag Nr.: 21.766.641 von whyso am 23.05.06 22:54:20

Jungs und Mädels wir fliegen !! 5,35$

[whyso]

Antwort auf Beitrag Nr.: 21.766.849 von mikel_ann am 23.05.06 23:13:17

Wo du recht hast...

Real-Time ECN | Order Book Get Real-Time ECN for:

NOVAVAX INC (RT-ECN)
Symbol: NVAX
Last Trade: 5.38 5:13PM ET
After Hours Change: 0.70 (14.96%)
Today's Change: 1.19 (28.40%)
Bid: 5.21
Ask: 5.36

[mikel_ann]

Antwort auf Beitrag Nr.: 21.766.874 von whyso am 23.05.06 23:15:59

Und ich Idiot habe vorhin 500 Stück für 4,75 verkauft.

[whyso]

Antwort auf Beitrag Nr.: 21.766.953 von mikel_ann am 23.05.06 23:25:02

Tja, ich denke er hier >>>EVANS GARY C<<<< hat deine 500 stk (u.a.) einverleibt...und nun wahrscheinlich gaaannnzz Tief in sein Depot zu recht gebettet..

[mikel_ann]

Antwort auf Beitrag Nr.: 21.767.044 von whyso am 23.05.06 23:35:27

Na der Rest liegt bei mir auch ganz tief und fest.

(So als wäre er garnicht da und das schon seit letztem Jahr)

Aber hin und wieder tradet es sich mit denen auch ganz gut.

[kafutznik]

Nachbörslich über 3 Millionen Aktien gehandelt 3,38


http://quotes.nasdaq.com/aspxcontent/ExtendedTradingTrades.a…

Heute gehts rund

[spontanix]

Ich gehöre ja meistens zu den optimisten und handele auch gerne mal ins fallende messer
Aber jetz gehöre ich auch zu den schönmalern*gg
Habe mal pusherbrief-like ne zeichnung gefertigt und ich wette hiermit das es auch so eintreffen wird
Novavax up2 5eur innerhalb der nächsten 7 Wochen!
Meine Zeichung erklärts von selbst*gg*
Es gab aus dem gesunden Anstieg einen Ausreißer nach oben und dann die aussergewöhnliche Korrektur unter den gesunden Anstieg, dieses unsichtbare gap wird sich schließen.

Die Erhöhung des Kapitals durch neue Shares leigt auf der Hand:
Eigene Medikamente -> und es laufen ja wirklich mehrere in der Pipeline, klinisch zu testen kostet eine Menge Geld, deswegen ist es nicht tragisch das man noch kein Geld “verdient“ (KGV) Es befinden sich meiner Meinung nach 2 „Geldquellen“ in Phase 3, den abschliessenden Tests vor der Zulassung, wovon schon 1 Vermarktungs-Deal mit Esprit abgeschlossen ist
Ein Zitat:
VLPs are the hot thing in vaccines now,"…. "Using viruslike particles, you can make a vaccine for five or 10 targets, all in the same vaccine. So the coverage of protection from the vaccine could be broad. Novavax, we believe, is one of the leaders in VLP technology.
Für mich ist Novavax einer der Ansprechpartner, für Partnershaften in diesem Interessengebiet. Und solange
Die eigenen Präparate noch in Phase 2 oder noch früher sind, wird so der Kostenanteil gedeckt.

Diesen Text habe ich gestern Abend geschrieben (konnte aufgrund unerreichbarkeit des WO-Servers nicht Posten ), ohne auf den Preisverlauf an der Nasdaq zu beobachten , aber 5,50 dollar Nachbörslich ist ja wohl der Hammer!

[e.1]

hallo leute,
profitiert denn cbmx davon. sie sah ja gestern eher dümpelig aus. erhoffe mir aber auch hier noch gute, steigende kurse.

zum glück habe ich bei nvax durchgehalten und nicht verkauft, puh.
gruß
e.1

[Vervain]

und was ist denn das fürn Kurs den Wo anzeigt?

[spontanix]

noch gar keinen,
pari wäre um die 4,19eur auf den nachbörslichen kurs.
mal sehen es kann jetz auch wieder zu schnell gehen
d.h. die daytrader werden wieder wie die maden angelockt
e.1 : nur ned die fühler fallen lassen , dachte auch was ich mir da fürn teil ins depot legte letztes jahr , als es von 3,59 auf knapp 2,20 ging, aber nachkaufen ist halt alles und was dann kam ist bekannt... hätte mich gerne bei 3.11 eingedeckt, aber musste ja wieder explorer kaufen

[e.1]

@spontanix
ich bin immer wieder platt, mit welchen reaktionen diese aktie reagiert.

hoffe bei cbmx auf eine ähnliche erholung.

gruß
e.1

[2375]

Antwort auf Beitrag Nr.: 21.770.935 von spontanix am 24.05.06 09:08:08

Ich auch (Explorer kaufen...)

[2375]

Antwort auf Beitrag Nr.: 21.771.690 von 2375 am 24.05.06 09:35:32

Ich bin alledings immer noch unsicher, wie weit die Korrekturen an der Nasdaq noch gehen und wie stark NVAX davon betroffen sein würde.

Von der Aktie an sich bin ich überzeugt, aber in einem weiteren Abwärtstrend weiß man halt nie was kurzfristig passiert und wann der richtige Einstiegszeitpunkt ist.

[spontanix]

als volaachternbahn kann man bei nvax keinen perfekten einstiegspunkt machen, bin zb bei 3,87 wieder rein, es ging bis 3,11 nach unten, hätte gerne nachgelegt.. naja
da es langfristig aber nach oben geht muss man für sich entscheiden ob man paar cent mehr ausgibt/ausgeben kann.
alle kurse unter 4 euro würde ich aktuell als kaufkurse benennen, was heute wieder schwer ist, da gestern die post abging.
aber da ist der hund der sich in den schwanz beisst, da es nun weiter nach oben gehen kann, aber auch erstmal wieder knapp unter die 4.. es gibt keine richtige ansage, wann man rein geht.
wenn man nvax will , kauft man es, aber man darf ned nervös sein, oder man lässt noch was geld über, um evtl nachzukaufen ( und ärgert sich evtl in nachhinein nicht doch alles reingesteckt zu haben)
wenn jetzt eine news kommt wie sommer/herbst 2005 gehts wieder an die 8 euro ohne probs (mist schon wieder am pushen tztz)

[Vervain]

Antwort auf Beitrag Nr.: 21.770.257 von Vervain am 24.05.06 08:43:44

Explorer kaufen. Meint ihr damit sowas wie Greater Sooner???gggg. den Fehler hab ich auch gemacht.g.

[2375]

Antwort auf Beitrag Nr.: 21.773.427 von spontanix am 24.05.06 10:41:54

Ich halte jetzt schon fast ein Jahr eine größere Position NVAX, welche sich natürlich super entwickelt hat, aber am Hoch verkauft hätte ich natürlich gemessen am jetzigen Kurs schon einen Riesengewinn gemacht, den ich aber aus Gründen der Haltefrist ( Steuern ) nicht realisieren wollte.

Schaun mer mal was in den nächsten Tagen passiert, wegen nachlegen, weil es heute so aussieht als wenn der NVAX Kurs nach oben läuft.

[2375]

Antwort auf Beitrag Nr.: 21.773.835 von Vervain am 24.05.06 10:56:52

jaaaa, den von dir genannten zwar nicht, aber upda war auch wieder einmal dabei.....

[mikel_ann]

NVAX kann sich in den nächsten Jahren wirklich noch super entwickeln.

Das "Hoch" wurde nicht durch "fundamentales" beendet, sondern
durch Journalismus, so wie jetzt unter Umständen auch das "Tief"

Der Handel in D ist leider uninteressant, obwohl ich die grösste
Position in D habe. Aber 920 Stücke in FFM ist nicht der Bringer.

[AidanQ.]

...habe mich die letzten tage mehr im us board rumgetrieben. aber selbst die amis sind gestern überrascht worden. es fällt schwer, bei dieser vola cool zu bleiben, aber nun denke ich werden wir einen widerstand nach dem anderen abbauen. nächster halt oberhalt der 100ma, sprich 6,xxx$

gruss aidan

[Vervain]

Antwort auf Beitrag Nr.: 21.774.337 von mikel_ann am 24.05.06 11:15:43

also ich bin ja ein reiner Aktienanfänger...bissel zu mutig vielleciht ab und an...und deswegen wage ich auch bissel "blöde" Fragen zu stellen.
Mir ist klar, dass Novavax ein US Aktie ist, natürlich ist der Handel in den US der, der wesentlich ist. Letztendlich hängt sich der Kurs in Frankfurt doch dann immer dem Kurs in den USA an oder? Irgendwann im Laufe des Tages wird er sich angleichen. Gestern gings in USA hoch - also bei uns auch heut vormittag. Wir haben jetzt die Chance "vor" den USA zu "verkaufen" und evtl. Gewinne mitzunehmen - oder eben auch nicht. Klar. Heut abend um 21 Uhr kann ich als "Normalo" nicht mehr ins Börsengeschehen eingreifen.

Ist DARUM der Handeln in D uninteressant? Oder wegen der mageren Umsätze? Versteh ich nicht...

[spontanix]

magere umsätze ist relativ, da es nur zur zeit dürftig ist, sah schon mal anders aus
aber es ist so: die ersten kurse morgens sind die reaktion auf den abend drüben, dann heisst es abwarten und auf 15.30 warten, ausser wenn vorbörslich news kommen, dann gehts auch hier um die mittagszeit los.aber normla warten wir auf die ersten kurse von drüben.
wenn vormittags/mittags großer handel ist, sind bestimmt auch schon amis hier, und dann kann man sagen, um 15.30 ist die hölle los
so ha ichs beobachtet, kann aber auch anders sein, da jeder blickwinkel anders ist.
drüben zu kaufen ist auch eine sache des volumens, für 200 aktien gehe ich ned nach amiland zum kaufen.
eine rolle spielt auch der eur/dollar-kurs
ich tu lieber was für die deustche wirtschaft und spendiere der codi die ordergebühren

[AidanQ.]

..vervain.

ist der umsatz so dünn wie in deutschland, kannst du mit diesen crossboardergeschichten nichts anfangen. der kurs, den du in frankfurt siehst, ist ein reines spiel des marketmakers (händler vorort)und spiegelt nur bid/ask-verhältnis aus den usa wieder, aber nicht die wirkliche nachfrage. mit den richtigen tool kannst du auch nach 20h in den usa kaufen oder verkaufen, sollte man sich überlegen, wenn öfters in den usa gehandelt wird

gruss

[mikel_ann]

Antwort auf Beitrag Nr.: 21.774.668 von Vervain am 24.05.06 11:28:28

Ja das hat Aidan ziemlich gut getroffen.

Sponanix bei 200 Akazien (ca.1000$) sind das bei Nordnet ca. 20E Gebühr Kauf und Verkauf oder 10 Cent je Stück, das ist schon etwas heftig. Fürs Traden sollte der Einsatz doch etwas höher sein.

Die Kurse in Deutschland sind aber wirklich Zufall.

Aus Spass habe ich kürzlich in FFM ein par ELN aus dem Ask
deutlich unter USA gekauft, der Makler ist dann offensichtlich aufgewacht und ich habe nur enige Minuten dieselben zu wesentlic höherem Kurs wieder ins Bid verkauft.

[Vervain]

Antwort auf Beitrag Nr.: 21.776.092 von mikel_ann am 24.05.06 12:18:34

DANKE!
Ihr seid super!

[e.1]

meiner meinung nach, der geringeren umsätze wegen.
ich kaufe auch lieber in amiland.

gruß e.1

[AidanQ.]

...pre-market auch nicht schlecht

http://www.level2quotes.com/

nvax als symbol eingeben

[mfierke]

[e.1]

@aidan
über welchen onlinebroker handelst du.
ich bin bei nordnetonline, fnd sie bisher nicht zu teuer. da ist die dab teurer meiner meinung nach.

gruß
e.1

[2375]

Antwort auf Beitrag Nr.: 21.774.337 von mikel_ann am 24.05.06 11:15:43

Ich halte meine gesamte Position in D, kann aber nach Auskunft meiner DresdnerBank, diese auch in USA verkaufen, was mir wegen des allgemein größeren Volumens auf jeden Fall angeraten erscheint. Vor allen Dingen wenn mein Wunschkurs von ca. 12,-- EUR erreicht wird. Na ja, ich träume gerade...

[kafutznik]

Wahnsinns Volumen Vorbörslich 5,50 USD

[AidanQ.]

Antwort auf Beitrag Nr.: 21.779.556 von e.1 am 24.05.06 14:20:51

..ich handel über consors (als heavytrader) habe über meinen activtrader realtime kostenlos und kann an allen börsenplätzen weltweit handeln.
service und support bei consors ist sehr zufriedenstellend, aber etwas teurer als bei traderbanken wie flatex und co.

[AidanQ.]

...ach ja, gehandelt wird immer in landeswährung, ist wichtig bei sl's und limitangaben

greets aidan

[e.1]

danke dir aidan

[kafutznik]

NOVAVAX INC Quick Quote: NVAX 4.68 (Even)




Market Pulse Announces Its AM Stock Picks for Wednesday, May 24, 2006: YHOO, PKCY, JDSU, NVAX
5/24/2006

ATLANTA, May 24, 2006 (PRIMEZONE via COMTEX News Network) --
Market Pulse is pleased to announce the following stock recommendations. Bernard Schmitt of Market Pulse states, "These notable stocks should be watched because they look great from a fundamental and technical perspective." Bernard possesses many years of experience in the financial industry recommending and evaluating stocks. He rates them as follows:

Yahoo! Inc. (Nasdaq:YHOO): Market Outperform

Park City Group Inc. (OTCBB:PKCY): Attractive

JDS Uniphase Corp. (Nasdaq:JDSU): Bearish

Novavax Inc. (Nasdaq:NVAX): Attractive

Recommendation Meanings

These recommendations are investment opinions of Market-Pulse.com and reflect the stock's potential to move over the next one to four weeks of trading. This analysis is done from a technical and fundamental perspective.

After The Bell Market Commentary

According to Bernard Schmitt, "On Tuesday, gold and oil prices rose. Shares of alternative fuel companies rose as crude oil flirted with the $72 a barrel mark before settling at $71.76. Gold closed up $16 at $673.80 an ounce. The Dow lost 26.98, or 0.24 percent, to 11,098.35, after adding as much as 77 points. The Nasdaq composite index fell 14.10, or 0.65 percent, to 2,158.76. The Standard & Poor's 500 index dropped 5.49, or 0.43 percent, to 1,256.58. The Russell 2000 index advanced 3.96, or 0.55 percent, to 711.29."

About Market-Pulse.com

Market Pulse LLC, the owner and operator of Market-Pulse.com (collectively referred to as "MP"), is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. MP is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. MP's goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. MP provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. MP offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.market-pulse.com.

Information contained herein is the opinion of MP and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties, disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated one hundred forty thousand dollars from Park City Group, Inc. for its current coverage. In addition, MP has fifty thousand dollars pending from Park City Group, Inc. For past coverage, MP was compensated twelve thousand five hundred dollars from Park City Group, Inc. In addition, for past coverage of Park City Group, Inc., MP was also compensated from a third party shareholder two hundred fifty thousand free trading shares of stock in Park City Group, Inc. To date, MP has sold these shares for proceeds totaling seventeen thousand nine hundred dollars. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services.

This news release was distributed by PrimeZone, www.primezone.com

SOURCE: Market Pulse

INVESTMENT OPINION

Market Pulse Bernard Schmitt [phone] [e-mail]

(C) 2006 PRIMEZONE, All rights reserved.

[AidanQ.]

...die ami's

http://www.paperboy.nl/index.cfm?PID=AEB03A86-A14D-4BE9-AD58…

[radic]

obercool

[e.1]

hoffentlich ist diese bläde traderei bald vorbei.
es sah so schön ais 17% plus und dann das zum Schluss.
Aber es hat mal wieder gezeigt wieviel potentiel hier drin steckt. also dran bleiben.

ich hoffe, dass es heute weider etwas nach oben geht.

gruß
e.1

[spontanix]

knapp unter 5 dollar auch nachbörslich, pari wären 3,89 etwa, pasts schön, war zu extrem der 25%er
da hatten die daytrader wieder gute geschäfte
so mal wieder spätschicht auf kirchl. feiertag = 150% zuschlag netto < das wär doch mal was für nvax ( hoffe die great coalition lässt die finger von den schichtzulagen )

getreu dem motto nvax up2 5eur


Concerns that the deadly bird-flu virus may have been spread from human to human in an Indonesian family hurt Asian currencies and European airlines on Wednesday as shares of niche vaccine makers rallied.

Currencies, including the Indonesian rupiah and the Australian dollar, edged lower after the World Health Organization said it couldn't rule out that a father in Indonesia caught the H5N1 strain of influenza from his son.

The man was the seventh person in that extended family infected with the H5N1 virus and the sixth to die. So far, the disease, which carries an extremely high mortality rate, has been most prevalent in Southeast Asia.

Almost 130 people have died from the virus since it was first identified around the turn of the millennium. Human cases of the disease, albeit rare, have been reported throughout Asia and, more recently, in Europe and Africa. Fear over the spread of avian flu has led authorities to destroy millions of birds, especially those raised for human consumption.

If the Indonesian case were confirmed, it would be the first known human-to- human transmission of the disease. World health experts have warned that the H5N1 virus could mutate into a strain that is easily transmitted among humans, thereby setting the stage for a catastrophic pandemic. To date, the bulk of the human cases involved people who have had extremely close contact with or ingested undercooked meat from sick birds.

In a statement released late Tuesday, the WHO said that it was still investigating whether human-to-human transmission of the disease, which kills by destroying the lungs, was the cause of the man's infection.

Shares of vaccine makers rallied on the news, with most already having been awarded some sort of government contract to work on avian-flu vaccines or therapies.

Generex Biotechnology Corp. (GNBT) was most the biggest gainer, with shares soaring 10% to close at $2.03 , followed by BioCryst Pharmaceuticals Inc. (BCRX) , up 10% at $12.95. Novavax Inc. (NVAX) shot up 6% to $4.98, while Peregrine Pharmaceuticals Inc. (PPHM) leapt 7% to $1.51.

Other notable advancers were biotech companies Vical Inc. (VICL) , Hemispherx BioPharma Inc. (HEB) , and Avant Immunotherapeutics Inc. (AVAN) . Flu-vaccine maker MedImmune Inc. also climbed, rising 5% to $30.83. Gilead Sciences Inc. ( GILD) , which developed the anti-influenza drug Tamiflu, now marketed by Roche Holding, was up 3% at $55.50.

The world's largest vaccine makers, however, appeared to be relatively unaffected by the news.

GlaxoSmithKline PLC (GSK) , which also markets the antiviral drug Relenza, was down almost 2% at $55.01. Sanofi-Aventis (SNY) slipped 1% to $47.10, while Novartis AG (NVS) , which just bought flu-vaccine maker Chiron, was down 2% at $ 55.86. All the companies were recently awarded contracts by the U.S. government to develop speedier methods for mass-producing flu vaccines.

The rupiah was down as much as 1%, and several other Asian currencies also declined against the greenback. In share trading, the Jakarta Composite Index was flat.

Much of the foreign-exchange losses were reversed during European trading hours.

Companies tied to the travel business also declined, including Air France-KLM (AKH) and British Airways (BAB) .

Also falling were the U.S.'s leading poultry suppliers.

Tyson Foods Inc. (TSN) slid 3% to $16.20, as Pilgrim's Pride Corp. (PPC) lost over 1% to close at $26.14.

[e.1]

trotzdem geht es abwärts, grr.

[mikel_ann]

Antwort auf Beitrag Nr.: 21.795.579 von e.1 am 25.05.06 16:07:27

Zwischenzeitlich aber auch mal sprunghaft aufwärts

[whyso]

Background on the Current Outbreaks
Influenza A (H5N1) is an influenza A virus subtype that occurs mainly in birds and is highly contagious among birds. Outbreaks of highly pathogenic H5N1 among poultry and wild birds are ongoing in a number of countries. H5N1 does not usually infect people, however, a small number of human cases of H5N1 infection have been reported in association with these outbreaks. Most of these cases have occurred from direct or close contact with infected poultry or contaminated surfaces. And while the H5N1 virus does not now infect people easily, infection in humans is very serious when it occurs; so far, about half of people reported infected have died. Rare cases of human-to-human spread of H5N1 virus may have occurred, but there is no evidence of transmission beyond one person.

Nonetheless, because all influenza viruses have the ability to change, scientists are concerned that H5N1 virus one day could be able to infect humans and spread easily from one person to another. Because these viruses do not commonly infect humans, there is little or no immune protection against them in the human population and an influenza pandemic (worldwide outbreak of disease) could begin. Experts from around the world are watching the H5N1 situation very closely and are preparing for the possibility that the virus may begin to spread more easily from person to person.

http://www.cdc.gov/flu/avian/outbreaks/current.htm#backgroun…

[spontanix]

ich hab gerade bischen gestöbert und da findet bald in amsterdam eine bigplayer konferenz statt, leider ist novavax nicht unter den vorsprechern dabei, aber ist doch eine gute möglichkiet kontakte zu knüpfen :
http://www.phacilitate.co.uk/pages/spring_vaccine/index.html
und vor allem hier:
http://www.phacilitate.co.uk/pages/baltimore_vac/index.html

[spontanix]

( hab da jetz mal ne mail an nvax geschrieben )
mal sehen was da raus kommt, denn die themen sind wohl sehr wichtig:

INFLUENZA VACCINES
• Updates on pandemic preparedness plans from key stakeholders from Europe, North America, Asia and Oceania
• In-depth analysis of the evolving influenza vaccine market
• Clinical data, trial design and product development strategies for
- Leading cell culture manufacture technologies in development
- Dose sparing and immunogenicity boosting technologies in development - novel adjuvants and delivery devices
Top

CORPORATE STRATEGY
• Vaccine marketplace in 2010
- What will it look like and how can you adapt your current business model to meet its demands?
• Global health
- Latest funding plans of the leading NGOs
- Industry strategies for commercialising developed/developing world vaccines
• Opportunities in Asia
- Keys to forming and maintaining successful partnerships with Asian vaccine
companies
• Finance
- Defining the keys to successfully securing funding from big pharma, NGOs and
Government bodies
Top

R&D & MANUFACTURING STRATEGY
• Novel technologies in the clinic
- Next steps for antigen delivery platforms in development
- Common lessons from the development of therapeutic vaccines for different
applications
• Influenza vaccine technologies
- Leading cell culture manufacture technologies in development
- Dose sparing and immunogenicity boosting technologies in development - novel
adjuvants and delivery devices
- its demands?
• Global health
- Latest R&D plans of the leading NGOs
- Industry R&D strategies for developed/developing world vaccines
• Opportunities in Asia
- Practical pros and cons of offshoring/outsourcing R&D and manufacturing
to India and the Far East
Top

REGULATORY STRATEGY
• Exploring and clarifying key novel guidelines and legislation on both sides of the Atlantic from both regulator and industry perspectives:
- EU CTD
- Pros and cons of de-centralised versus centralised process in the EU
- Qualifying for conditional approval in the EU
- Efficiently meeting novel post-licensure commitments in the US and Europe
Top

[whyso]

Hi Spontanix, gute Arbeit

Hier findest du viele antworten auf die "noch" offener Fragen im Bezug auf H5N1:

http://www.avianflutalk.com/forum_posts.asp?TID=8766

The plot thickens,
Whyso

[e.1]

hat jemand eine ahnung, weshalb cbmx gestern so abgegeben hat.
ich bin auf den heuten tag gespannt,


gruß
e.1

[whyso]

Wrong board für ein CBMX Rede & Antwort ABER.. ich denke man wartet der bald kommenden "splitt" ab bevor CBMX frei davonlaufen darf, bis dahin wird bei dünnen Handelsvolumina "billigst" eingesammelt...

Gruß & good trades,
Whyso

[e.1]

hallo whyso,
ich weiß hier nvax drüben cbmx, aber da ist so wenig los, da tummlöe ich mich lieber hier, in der hoffnung schneller antwort zu bekommen.

gruß
e.1

[AidanQ.]

...außerdem steigt der kurs so schöööön (bis jetzt)

[mikel_ann]

Antwort auf Beitrag Nr.: 21.816.300 von AidanQ. am 26.05.06 16:13:34

Da geht aber nicht viel +/- 10 cent Daytrading

[whyso]

NVAX Timeplan von Bioinvestor @Yahoo...
----------------------------------------
Next Thursday is June 1st
by: biovestor123
Long-Term Sentiment: Strong Buy 05/26/06 11:00 pm
Msg: 240974 of 240983

Sorry to state the obvious, but Rahul said that preclinical results would be released in June. I think that this month could be the turning point for this stock as many pipelines start to bear fruit (see timeline below).

As per the last conference call, the CDC will likely be testing Novavax's vaccine against the live H5N1 virus. If they are moving forward with a CDC follow-up project, I would guess that the U.Pitt study saw positive results with Novavax's VLP vaccine in eliciting an immune response in animals.

It also seems as though Rick Bright's connections with his former colleagues at the CDC are paying off. These connections may be important to opening key doors for us in the future.

The follow-up study at the CDC with the live virus also fits with Novavax's stated timeline for an IND and phase I trials in Q4. So, I would expect the U.Pitt. results this month and CDC H5N1 vaccine results(hopefully both strains of the live virus)in mid to late Q3.

Some Possible Milestones

June - U.Pitt VLP vaccine and Novasome data
July - ?
August - CDC VLP vs. live H5N1 virus data + Novasome data
September - 1.)Potential $50-75 in government funding. 2.) IND filed to start H5N1 VLP vaccine and Novasome trials
trials
October - HIV vaccine data (Rahul said within 6 months on the last call)
November - Human H5N1 vaccine trials start phase I in the US and India.
December - Possible Drug Delvery Partnerships announced (Rahul said by the end of the year we should know more about these).

Dominoes will begin to start falling in the next few months. If we assume positive preclinical/clinical results in HIV and H5N1 (such as others have had with the HPV VLP vaccine) and if we are able to improve the balance sheet with grants, revenue from Estrasorb and other partnerships - where should our stock be by the end of the year?
And if we meet these milestones, 2007 should get very interesting as we likely become a profitable company.

[spontanix]

das sind doch mal wieder sehr erfreulich, was man da zum frühstück hört
hoffen wir es wird so ähnlich ablaufen*g*
gruß und schönes we...
ach ja pari 4.02

[AidanQ.]

...nächste woche test der 6,5$ marke, nice we.

[whyso]

Lesen & staunen (Ich denke NVAX's "Stunde der Wahrheit" ist hiernach wirklich nicht mehr weit Entfernt)

Three more bird flu deaths confirmed

KUBU SIMBELANG, North Sumatra (AP): The biggest case yet of humans possibly infecting others with bird flu has prompted the World Health Organization to put the maker of the anti-viral drug Tamiflu on alert to ship the global stockpile for the first time if needed.

The alert came as three more bird flu deaths were confirmed in Indonesia, bringing the total to 36 in a sprawling country that critics say has been slow to implement tough measures to stop the spread of the disease.

The U.N. health agency alerted Swiss drug maker Roche Holding AG last week as part of its standard operating procedure to keep quick access to the stockpile during a European holiday, but said no shipment or further action was expected for now.

"We see this as a practice run," WHO spokesman Dick Thompson cautioned.


http://www.thejakartapost.com/detaillgen.asp?fileid=20060528…

[whyso]

"Despite the cluster of deaths, the virus has not mutated into a form easily passed among humans, experts said. Scientists have seen examples of bird flu passing between blood relatives in a handful of smaller cases, leading to speculation of a possiblegenetic vulnerability."

und somit "exitus" Tamiflu-enter VLP...

We will see,
Whyso

[spontanix]

hallo,

was ist eigentlich von diesen bezahl-diensten zu halten, die analysen etc anbieten? l@@k:

30-May-06 Market Edge N/A Market Edge Equity Research Report 4 $10

29-May-06 Pechala's Reports Lubomir Pechala NOVAVAX INC (NVAX=US) 2-weeks forecast 1 $10


29-May-06 Black Box Investing N/A Black Box Investing Technical Analysis Report of NVAX: An in-depth examination of the current technical condition of NVAX. This report analyzes the major technical indicators including their past performance and profitability. 18 $25

29-May-06 BiotechWatch LLC Alfred Mansour Ph.D. BiotechWatch's profile of Novavax tracks products in clinical development, cash on hand, clinical trial status, milestones, corporate alliances, and current stock prices and fundamentals N/A $100

mich würde ja diese blak box pdf und der market edge interessieren , aber will dafür keine kohle ausgeben

[spontanix]

hm der marketmaker ist scho nen vogel
da verkloppt einer 75(!) aktien und lässt dadurch den kurs um 9 cent fallen

[AidanQ.]

Antwort auf Beitrag Nr.: 21.837.228 von AidanQ. am 27.05.06 18:20:28

[spontanix]

na... warum wurde denn kein kurs bei den 5,35er $-kursen gemacht alter schlingel der
sähe doch fein aus im ohlc*g*

[AidanQ.]

...kaufen hier die big boys?
http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_tic… gp=0&x=16&y=6&i=2&hdate=" target="_blank" rel="nofollow ugc noopener">
http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_tic… gp=0&x=16&y=6&i=2&hdate=

[mikel_ann]

Antwort auf Beitrag Nr.: 21.876.546 von AidanQ. am 30.05.06 17:38:56

Ich weis nicht, aber diese Pennytraderei geht mir auf den Senkel.

50K ins BID kaufen (bedienen lassen) und 5 ct teurer wieder im ASK
verkaufen..

[AidanQ.]

...das hat doch system. schau dir mal die schlussauktion wieder an. da sind die ganzen trader nicht dabei. 13% instis heute. denke, dass da noch was geht demnächst. für so ein schlechtes umfeld hat sich nvax gut behauptet.

ciaoo aidan

[AidanQ.]

..da wird nach unten alles aufgesammelt.zudem wurde das gap bei 4,80$ getestet und geschlossen

[e.1]

dann hoffe ich, dass die amis zum wochendende nicht wieder alles verkloppen.
es wird langsam zeit dass sie wieder steigt unsere nvax (+cbmx)

[AidanQ.]

...vorbörse bei 5,45$

[AidanQ.]

http://news.antara.co.id/en/seenws/?id=13714

[e.1]

so langsam aber sicher macht es keinen spass meh. hier muss man wirklich viel geduld mitbringen.
ich hoffe, dass die andere richtung sich baldigst einstellt.

gruß e.1

[e.1]

weiß jemand was hier los ist, dass es so runter geht?

[spontanix]

ist sehr ruhig geworden.. naja übern sommer hinweg dürfte wohl einiges passieren, großartig runter gehts ja ned.. dümpelt um die 4 euronen rum, soll ned stören, wenn man long ist

[whyso]

Eben Spontanix, so isses

[AidanQ.]

...relativ stark heute

[AidanQ.]

...premarket 5,25$ 25ooo shares

[e.1]

sah heute abend leider anders aus.
ich hoffe nur, dass sich da insgesamt mal wieder was nach oben bewegt.

[kafutznik]

Nachbörslich ging es richtig zur sache weiß einer warum ??

Hohes Volumen hoch bis an 5 Dollar


http://quotes.nasdaq.com/aspxcontent/ExtendedTradingTrades.a…

[Vervain]

Antwort auf Beitrag Nr.: 22.159.556 von kafutznik am 17.06.06 12:14:17

vielleicht wegen des Vogelgrippe-Verdachts in Kanada???

[nort.]

[AidanQ.]

...sollten wir tatsächlich auf wochenhigh ins weekend gehen?

[whyso]

Antwort auf Beitrag Nr.: 22.252.372 von AidanQ. am 23.06.06 20:12:17

Hi Aidan...NVAX hat gestern neuen Auftrieb vermeldet bekommen: http://biz.yahoo.com/ap/060622/ahead_of_the_bell_bird_flu.ht…



Der "trend" will auch unbedingt wieder im Richtung norden marschieren wie es momentan aussieht

Schönes Wochenende,
Whyso

[radic]

sie lebt

[AidanQ.]

...hi folks, das sieht ja richtig gut aus. zur zeit outperformen wir den markt

[spontanix]

menno.. wenn man sich den kurs so quälen sieht bekommt man fast mitleid
hab letztens was dagegen getan bei 3,50

[Glück]

Antwort auf Beitrag Nr.: 22.254.725 von whyso am 24.06.06 07:55:51

Wie schaut´s denn nun mittelfristig aus

[kafutznik]

Schaut mal was Nachbörslich abging


http://quotes.nasdaq.com/aspxcontent/ExtendedTradingTrades.a…

[whyso]

Die Russell Umstellung von letzten Freitag Abend lässt Grüßen, bei GNTA ging es umso heftiger im afterhours trading zur sache, ich schätze dort kommt was ganz gewaltiges auf uns zu demnächst...

Übrigens vaccinelösungen werden wieder richtig "sexy"
http://www.cancercompass.com/cancer-news/1,7870,00.htm

Bis die Tage,
Whyso

P.S.(off topic-) Ein evtl. nutzliche Link für (Dienstag Abend) @ alle hoffnungsvollen Italianer die bei uns hier im Forum rumtummeln
http://www.brothers-of-destiny.de.dd13030.kasserver.com/rapi…

[Stochastic]

Na ich hätte @whyso's Wette doch eingehen sollen mit den 10€ im Mai!

[URL]http://www.tradesignal.com/content.asp?p=wpa/tsb/default.asp&fcid=1593602[/URL]
[URLChart öffnen]http://www.tradesignal.com/content.asp?p=wpa/tsb/default.asp&fcid=1593602[/URL]

Biotechs laufen schlecht....und zwar fast alle....wer einen langen Atem hat sollte nicht vergessen zwischendurch mal Luft zu holen....kann sonst ganz schön öde werden!

Grüße, Stochastic

[buxte]

Hallo @ all.

Wollte auch mal wieder hallo sagen.
Wie es aussieht haben wir noch keine Bodenbildung. Werde demzufolge noch etwas warten.

Alles Gute den Investierten.

buxte

[nort.]

[e.1]

minus 10% weiß jemand weshalb. gibt es irgendwelche nachrichten, weshalb es so abwärts geht.
macht echt keinen spaß zur zeit.

gruß e.1

[nort.]

Antwort auf Beitrag Nr.: 23.125.269 von e.1 am 27.07.06 22:11:24

vermutlich die Auswirkung von GSK

[e.1]

dann habe ich ja hoffnung auf erholung.
bin mal gespannt wie es nach meinem urlaub aussieht.

sonnige grüße

e.1

[idon]

Antwort auf Beitrag Nr.: 23.144.703 von e.1 am 28.07.06 07:26:04

Hi Leute,
hier ein vielsagender Link

http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_tic…

der Zug fährt bald los!!

Greets, Idon

[idon]

Antwort auf Beitrag Nr.: 23.365.892 von idon am 09.08.06 11:32:20

Naja, ich ging von ner anderen Richtung aus

[e.1]

ich ging auch von einer anderen richtung aus. minus 8%, das ist ja schon ein wirklich großes minus.
kann man nur hoffen, daß es wieder aufwärts geht.

gab es irgendwelche nachrichten, die dieses große minus rechtfertigen würden?

falls jemand infos hat, bitte melden!

gruß
e.1

[idon]

Antwort auf Beitrag Nr.: 23.450.716 von e.1 am 15.08.06 09:41:03

Hallo e1,
NVAX hat sich inzwischen wieder gut erholt, ich denke der Rückgang war auf Shorties, allgemeine Unsicherheit an den Aktienmärkten und speziell zu NVAX vor der Veröffentlichung der Zahlen zurückzuführen.
Zwischenzeitlich wurde NVAX auch gestern in den Rankings zu sectorperform hochgestuft, äusserst positiv

Bleibt nur zu hoffen, dass der Wert nach dem 13%-Anstieg auch dort bleibt, wo er ist und die Gewinnmitnahmen in Aussicht auf weiteren Anstieg sich im Rahmen halten.

NVAX bleibt extrem vielversprechend

Alles natürlich meine Meinung

Greets, Idon

[BeastyBloom]

Moin moin

Das hoffe ich auch - naja ich hoffe außerdem auf den Herbst und die Zugvögel. Letzten Herbst und Frühjahr konnte Novavax ja von der Vogelgrippe profitieren ... und ich hab es verpasst meinen Einsatz rauszuziehen ...... wieder Lehrgeld bezahlt - zumindest an entgangenen Chancen.

Wie man beim Militär früher immer sagte "Auf Kriegs- und Seuchenreiche Zeiten"

Greetz BB

[idon]

Antwort auf Beitrag Nr.: 23.476.357 von BeastyBloom am 17.08.06 02:26:34

Mojn,
hoffe eigentlich weder auf Krieg noch auf Seuche, auch wenn das zweite NVAX mit Sicherheit pushen wird. Naja, der erste H5N1-Fall drüben wird NVAX zur Rakete werden lassen. Auf diesen ertsen Fall warte ich sehnsüchtigst

Greets, Idon

[e.1]

das heraufstufen auf sectorperform scheint früchte zu tragen.

weiter so!!!!

schöne grüße an alle nvaxler+cbmxler

e.1

[idon]

Antwort auf Beitrag Nr.: 23.486.684 von e.1 am 17.08.06 19:09:02

Hi NVAX-ler,
ich denke, es wird bald so richtig los gehen, H5N1 wird richtig aktuell, hier die News:

H5N1 Mutations Confirmed
ROME - Aug 17/06 - SNS -- The H5N1 strain of avian influenza is moving back into the headlines with the confirmation a new strain has been found in Southeast Asia, along with outbreaks of the original virus.

The FAO warns this makes it clear vigorous implementation of recommended control measures is needed to prevent a further spread of the disease and sustain past successes in the region.

"Last month's HPAI outbreak in Thailand's Pichit province was caused by the same virus strain circulating in the area since 2003/04. The H5N1 virus thus remained alive in central Thailand in a reservoir of birds and poultry, most probably a mix of backyard chicken, ducks and fighting cocks," said Laurence Gleeson, regional manager of FAO's bird flu center in Bangkok today.


H5N1 Endemic in Thailand's Pichit Province
This indicates that the H5N1 virus is endemic in the area. While the number and size of outbreaks has been reduced, past control efforts were only partly successful.

On the other hand, the outbreaks in Nakhon Phanom and Vientiane were caused by a H5N1 virus strain previously not detected in Thailand and Laos. Instead, the virus is similar to recent isolates from southern China, suggesting that the virus spread from China to Thailand and Laos.

FAO recognizes that poultry trade across borders is continuing in Southeast and East Asia despite well-known risks to the governments and people in the region.

Countries are once more called upon to strengthen in-country as well as cross-border HPAI control measures, FAO added. In addition, regional HPAI networks need to be made stronger and sustainable with national and international support.

Recent sharing of information, epidemiological analysis and joint field missions to assess and control outbreaks in poultry have resulted in a better understanding of the month-old resurgence of bird flu in Asian countries such as Cambodia, Laos and Thailand.


Bird Flu In Indonesia Requires Greater Vigilance
"Continuing outbreaks in China, recurrence in Cambodia, Laos and Thailand, and the steady march of the disease in Indonesia underline the need for heightened vigilance in other Asian countries to prevent and detect any resurgence or introduction of the deadly bird flu virus. Timely reporting and sharing information continue to be crucial," warned He Changchui, FAO's Regional Representative for Asia and the Pacific.

The endemic presence of bird flu over the last three years coupled with the proven inroads of new virus isolates into already affected countries makes a redoubling of efforts at both national and regional level essential, FAO noted.

"We are at another critical juncture of fighting against the bird flu situation in the region," emphasized Mr He. "Some countries can beat back occasional bird flu reoccurrence, but poorer countries still need long-term work - and for that long-term funding is an absolute necessity - to strengthen veterinary services and build up transboundary animal disease containment programs," he added.

Governments in the region and FAO are working to tackle the bird flu problem at its source, but have so far only received a fraction of the $308.5 million needed. So far, Japan, USAID and the Asian Development Bank are the main donors in the region.

zu lesen unter
http://www.agreport.com/open/210316.phtml

die Richtung dürfte gegeben sein !!

Greets, idon

[idon]

Antwort auf Beitrag Nr.: 23.492.333 von idon am 18.08.06 10:21:37

äusserst interessanter Artikel, und nicht von nem Käseblättchen, ist immerhin der SPIEGEL, lesenswert und logischerweise die Meinung aller NVAX-ler wiederspiegelnd, hier nachzulesen:

http://www.spiegel.de/wissenschaft/erde/0,1518,432512,00.htm…

greets, idon

NB: whyso nicht mehr dabei??

[idon]

Antwort auf Beitrag Nr.: 23.532.101 von idon am 20.08.06 22:41:53

und hier http://www.netzeitung.de/wissenschaft/433614.html lesen:

Im Herbst drohen viele neue Vogelgrippe-Fälle

19. Aug 13:51



Vogelgrippe-Notfallkoffer eines Arztes

Das für Tierseuche zuständige Friedrich-Loeffler-Institut befürchtet einen baldigen neuen Ausbruch der Vogelgrippe. Denn zu Zeiten des Vogelzugs könne das Virus sich viel besser ausbreiten.

[idon]

Antwort auf Beitrag Nr.: 23.532.580 von idon am 20.08.06 22:57:58

sieht doch ganz gut aus für nen Wochenanfang

[derwolf1]

Unser Gary hat wieder zugeschlagen, er wird immer
gieriger diesmal 50.000 Shares zu 3,55 $.


http://www.secform4.com/insider/showhistory.php?symbol=nvax

[whyso]

Antwort auf Beitrag Nr.: 23.532.101 von idon am 20.08.06 22:41:53

Greetz Idon-klar bin ich noch dabei(allerdings auf'n etwas reudzierte Stufe als letztes Jahr).

Ich denke das Thema/Investment NVAX wird erst im laufe der kommenden Herbst überhaupt stattfinden...

Ab mitte September werden die shorties wieder flüchten!(müssen)-

Viele Grüße,
Whyso

P.S.Der Wildvogel Migration(Saison ab mitte Sept) könnte wie Benzin auf NVAX's neu entflammten Feuer wirken, obwohl das ganze im Bereich der"Vogel" eher als "Nebengeschäft" anzusehen ist

[idon]

Antwort auf Beitrag Nr.: 23.605.292 von whyso am 25.08.06 08:30:11

Hi whyso, freut mich sehr, wieder was von dir hier bei NVAX zu lesen .

Bin letzte Woche wieder was grösser eingestiegen und gehe davon aus, dass jetzt gerade im Vorfeld des Herbstes wohl jeder seine Shares einbehält, ausser beim Shorten, was aber auch heiss wird, denke ich.

Die allgemeine Richtung wird meiner Erachtens jetzt Norden bleiben, natürlich mit hier und da ein paar Korrekturen. Sobald der erste Vogel in den USA geniest hat, wird NVAX zur Rakete

Ich wünsche dir sowie allen anderen NVAX-lern ein schönes WE, auch wenn das Wetter nicht so mitspielt.

Greets, Idon

[nort.]

[Namaycush]

Sieht doch alles wieder etwas erfreulicher aus als im Sommer. Ich habe den Absprung verpasst im Frühling (war im Ausland Fischen) und habe deshlab gehalten. Die Story stimmt für mich immer noch und ich bin sehr zuversichtlich für die Zukunft. Ich habe bei dem Dipp auch immer die Inmtituionellen im Augebehalten - und dort hat sich ja nicht viel geändert - im Gegenteil!

Bin auch immer noch in CBMX investiert - dort aber z.Zt. noch im minus.

Allen weiterhin alles Gute!

Namaycush

[idon]

Antwort auf Beitrag Nr.: 23.678.668 von Namaycush am 30.08.06 09:32:55

hier lesen:

http://en.rian.ru/russia/20060830/53322081.html

greets, Idon

[idon]

Antwort auf Beitrag Nr.: 23.682.371 von idon am 30.08.06 13:05:01

Hi Leute,

das posten hält sich ja sehr in Grenzen, vieleicht noch zu wenig Umsatz . Drüben scheint NVAX schon was mehr Gesprächsthema zu sein, daher bin ich äusserst zuversichtlich und optimistisch, was die Entwicklung für diese Woche betrifft.

Was ist denn so eure Meinung?

Greets, Idon

[buxte]

[idon]

Hi Leute, sieht aus, als ginge es heute auch noch was runter, wird bestimmt interessant für eventuelle Zukäufe
Gruss, Idon

[AidanQ.]

Novavax, Inc. sagte heute, daß es die vor-klinische Prüfung der intranasalen Versionen seiner Grippeimpfstoffe in der Entwicklung angefangen hat und eine mögliche Alternative zum Ausüben dieser Impfstoffe von der Einspritzung bereitgestellt. „Dieses ist eine wichtige Zuführung für unsere vorhandene Technologie, weil es uns erlaubt, eine sogar ausgedehntere Bevölkerung zu erreichen,“ sagte Dr. Rick Bright, Vizepräsident Novavaxs der Vaccine Entwicklung. „Es gibt viele Teile der Welt, die Zugänglichkeit nicht zu genügenden sterilen Nadeln haben, zum auf eine Grippekrise zu reagieren.“ Historisch sind Grippeimpfstoffe ausgeübte zwar intramuskulöse Einspritzung gewesen. Jedoch hat die Weltgesundheitsorganisation (WHO) proaktiv alternative Anlieferung Methoden gesucht. „Das Problem mit Nadeln ist, daß Bedingungen in hohem Grade steril sein müssen, um Verschmutzung während der Massenschutzimpfung zu verhindern, die im Falle von einer Dringlichkeit stattfinden würde,“ Dr. gesagter Bright. Novavax forscht den intranasalen Anlieferung Weg mit der Firma nach, die Virus-wie saisonal und pandemic ist Impfstoffe des Partikels (VLP) in den vor-klinischen Modellen. „Unsere frühen Daten zeigen an, daß wir eine schützende immune Antwort mit dem intranasalen Impfstoff auslösen können, der so robust wie unsere intramuskulöse Formulierung ist,“ Dr. gesagter Bright. „Wir sind eifrig, diesen Weg der Anlieferung in der zusätzlichen vor-klinischen Arbeit, sowie menschliche Studien weiter zu erforschen.“ Mit der eigenen Technologie VLP der Firma verursachen Novavax Wissenschaftler einen Partikel, der zu einem Virus fast identisch ist, aber haben nicht das genetische Material des Virus, das für Reproduktion oder Infektion erfordert wird. Wenn sie in den Körper geimpft werden, haben diese Partikel die Fähigkeit, zu den Zellen anzubringen und eine natürliche immune Antwort auszulösen, die zum Schützen gegen Vireninfektion fähig ist. Novavax Wissenschaftler benutzen das Clade 2 Virus der Grippe H5N1 -- für die intranasalen und intramuskulösen Versionen seines pandemic Grippeimpfstoffs. Die Clade 2 Variante, gekennzeichnet in den Vögeln von China und von Indonesien, bevor sie nach Europa, den Mittlere Osten und Afrika verbreitet, ist für menschliche Infektion und Sterblichkeit über dem letzten Jahr hauptsächlich verantwortlich. Der WHO änderte vor kurzem seine Vogelanleitung der grippe H5N1, um anzuzeigen, daß pandemic vaccine Anwärter Viren von der Clade 2 Familie anstatt das frühere Clade zielen sollten 1 Familie. „, indem wir unsere Impfstoffe gegen die Clade 2 Belastung der pandemic Grippe herstellen, zielen wir Schutz gegen die gegenwärtigste Form dieses tödlichen Virus H5N1,“ Dr. gesagter Bright.

[radic]

thx,

aber irgendwie ist es mächtig ruhig geworden, we'll see

[idon]

Antwort auf Beitrag Nr.: 24.076.657 von radic am 21.09.06 09:08:44

Ruhe vor dem Sturm, hab irgenwo was niesen gehört

stay cool

greets, Idon

[AidanQ.]

...und noch was http://www.stockwatch.com/swnet/newsit/newsit_newsit.aspx?bi…

[AidanQ.]

...50 gerissen und die 100 im visier und dazu noch auf tageshoch geschlossen. mal sehen, wie es weiter geht

greets aidan

[radic]

yep,

könnte

[idon]

Hi, Leute, der Run scheint heute optimal und es sieht nicht danach aus, als würde sich daran was ändern
Greets to all NVAX-ler, Idon

[e.1]

das wäre wirklich sehr wünschenswert.
auch für cbmx

liebe grüße e.1

[idon]

Antwort auf Beitrag Nr.: 24.263.408 von e.1 am 28.09.06 17:58:17

Hi e.1, denke, dass es heute ziemlich zur Sache gehen wird, da hat einer 51.387 Aktien zu 4.04 USD erstanden, es wird wohl heute etwas bewegter werden, aber auf jeden Richtung Norden. Fast alle Märkte stehen im grünen Bereich.


It will be a nice day, greets, Idon

[AidanQ.]

...der premarket ging heute schon bis 4,20$,test det 4,50 immerhin möglich

greets aidan

[e.1]

wenigstens etwas.
kann jemand von euch etwas zu cbmx sagen, die macht mich recht nervös.
wäre wirklich sehr nett.

gruß e.1

[idon]

Antwort auf Beitrag Nr.: 24.280.915 von AidanQ. am 29.09.06 15:18:04

hatte eigentlich auch was anderes erwartet als die erlebte Entwicklung

aber da NVAX immer für ne Überraschung gut ist kann sich bis zum Abschluss noch einiges tun, sind wir mal optimistisch
Greets, Idon

[AidanQ.]

Antwort auf Beitrag Nr.: 24.286.964 von idon am 29.09.06 18:59:30

...soll das ein W werden

[radic]

jau

und es herbstelt

wenn die 4 nachhaltig fallen sind auch die 5 wieder drin

[mikel_ann]

Heute zeigt NVAX mal wieder etwas Stärke.
Vor etwas mehr als einem Jahr noch bei 1$. Schluss am TH

[radic]

und nochmal 5% sieht jetzt auch charttechnisch wieder interessant aus

[AidanQ.]

Antwort auf Beitrag Nr.: 24.540.494 von radic am 10.10.06 18:16:33

...kam heute.10.10.2006

Novavax Inc. 's hat einzigartiges Zellkultur-Fertigungssystem das Potential, bis zu einiges Million Dosen Impfstoff innerhalb sechs Monate einer Grippe, die, die Firma zu produzieren pandemic ist, die hier heute auf dem Weltimpfstoff-Kongreß gesagt wird. „, vorsterilisierte Wegwerfbioreaktorbeutel verwendend, kann Novavax ein vaccine Fertigungssystem anbringen und kann Impfstoffe, in weniger Zeit, als weit zu produzieren anfangen traditionelle pharmazeutische Herstellungsverfahren, die unzählige Leben möglicherweise speichern konnten,“ Tibor Nemes, Kopf Novavaxs der Betriebs sagten. „Die Herausforderungen des Produzierens genügenden Impfstoffs, um die Nachfragen der Vereinigten Staaten oder anderer Länder weltweit im Falle eines pandemic Ausbruchs der Grippe zu befriedigen sind schwierig,“ gesagter Nemes. „Wir nehmen eine proaktive Annäherung zu dieser Drohung.“ Schätzungen von den USmitten zur Krankheit-Steuerung und der Verhinderung projizieren, daß eine pandemic Grippe wahrscheinlich bis 7.4 Million Todesfälle global verursachen würde, mit Hunderten Millionen angesteckten Leuten. Novavax hat dieses bewegliche, Wegwerffertigungssystem benutzt, um Virus-wie Grippeimpfstoffe des Partikels (VLP) zu produzieren und hat jetzt scalability des Herstellungsverfahrens in einem kurzen Zeitabschnitt gezeigt. Gegründet auf vor-klinischen Studie Resultaten, haben VLP Impfstoffe das Potential, ausgedehnteren Schutz, häufig in einem Eindosen zur Verfügung zu stellen. Mit VLP Technologie verursachen Novavax Wissenschaftler einen Partikel, der zu einem Virus fast identisch ist, aber haben nicht das genetische Material des Virus, das für Reproduktion oder Infektion erfordert wird. Wenn sie in den Körper geimpft werden, haben diese Partikel die Fähigkeit, zu den Zellen anzubringen und eine natürliche immune Antwort auszulösen, die zum Schützen gegen Vireninfektion fähig ist. Impfstoffe VLP Novavaxs werden in der InsektZellkultur gewachsen, die Skala oben an den hohen Ergebnissen zugänglich ist. Historisch sind Impfstoffe in den Eiern produziert worden, die Monate der Vorbereitung und der großen, kostspieligen Produktionsanlagen erfordern. Das Kombinieren der Impfstoffe VLP Novavaxs mit einem flexiblen Fertigungssystem „verbessert drastisch unsere Kapazität, die sicheren und wirkungsvollen Impfstoffe zu produzieren und liefert die Geschwindigkeit und die Fähigkeit der Reaktion auf die Herausforderungen einer Grippe, die pandemic ist,“ gesagter Nemes.

[e.1]

na dann hoffe ich mal, dass es weiter aufwärts geht und cbmx mit provitiert.

grüße e.1

[AidanQ.]

...nvax scheint bald abzugehen. sehr stark,etwas mehr umsatz wäre nicht schlecht

[AidanQ.]

gerade im us board gelesen:

Sandman,
I think you know that I'm one of your biggest supporters and have nothing but respect for you.
However, that Novavax should remain silent, when Gary Evans takes up a new position as the Chief Executive of another company, is unacceptable to me.
Much needless speculation took place this morning, only because the company failed to keep their investors informed.
Of course, people become fearful when they read on a message board that the chairman of the company has a new job and there is no comment from the company.
Peter



...was hat das zu bedeuten?

whyso, was meinst du dazu und natürlich alle anderen auch

trotz allem wurde auf th geschlossen

[derwolf1]

Es sind Gerüchte von einer Übernahme im Umlauf.

Weiß jemand was davon ?????

[AidanQ.]

http://www.stockwatch.com/swnet/newsit/newsit_newsit.aspx?bi…

[AidanQ.]

...hat jemand noch eine einschätzung zu nvax? weitere news werden erwartet.die us kollegen sind auch positiver meinung, allen voran sandman...!

[AidanQ.]

http://www.stockwatch.com/swnet/newsit/newsit_newsit.aspx?bi…

[2Tuvok]

Schönen Tag

[whyso]

Tag zusammen-news von 8 Nov (aber könnte sehr "Kurs Relevant" sein demnächst

"Our data demonstrate the potential for a single vaccine to protect against a range of influenza strains," Dr. Bright said. "This can be a critical factor in a pandemic situation, since a new vaccine would not have to be created every time the virus mutates," Dr. Bright said. "Our goal is to demonstrate in the clinic that our single H5N1 vaccine protects against new mutations of H5N1 viruses." Novavax plans to begin human clinical trials of its pandemic influenza vaccine during the first half of 2007. "


http://www.marketwatch.com/News/Story/Story.aspx?guid=%7BB50…

Watch this space:


Keep the faith,
Whyso

P.S. Hallo Powerchord, hallo e.1. ich komm einfach nicht dazu Euch ein Antwort zu schreiben-SORRY- haben allerdings ein größere Posten CBMX mittlerweile in SIGA umgeswitcht-und dabei BÖSE VERLÜSTE realisieren müssen. GNTA, NVAX & SIGA bleibe ich weiterhin Treu

[e.1]

hallo whyso,
bei cbmx tut sich wohl was. hat ja gestern einen netten 10% sprung gemacht. ich hoffe, dass sie sich weiter erholt. auch ich bin im verlustbereich. hoffe, dass die verluste etwas kleiner werden.


gruß e.1

[2Tuvok]

Ist ja ne richtige Freude

[e.1]

bin gespannt wie weit sie rauf geht. könnte ruhig so weiter gehen.

gruß e.1

[AidanQ.]

...auszug aus dem us board von heute:

Quotes from the last conference call (Not rated) 10 minutes ago concerning HIV vaccine... "we have made an important breakthrough" regarding higher GP120 levels obtained by Dr. Gale Smith...

"we have tremendous good news to tell the public" (must withhold until patent protection is in place)

"would we like to get a 100 million dollar grant from the government? yes! " (I find it interesting that he stated that specific amount, and not a much lower amount.)

rez


Sentiment : Strong Buy

[BeastyBloom]

Weiß jemand was heute los war? 10% im Minus ist ja schon beachtenswert. Irgendwelche negativen Neuigkeiten, die ich übersehen habe?

Greetz BeastyBloom

[cyberhai]

Antwort auf Beitrag Nr.: 26.284.055 von BeastyBloom am 18.12.06 19:50:37

Hängt evtl. mit dem Wettbewerb zusammen:

http://biz.yahoo.com/bw/061218/20061218005287.html?.v=1

Gruß Cyberhai

[buxte]

Hallöchen,

wird ja wieder interessant.

buxte

[mikel_ann]

Antwort auf Beitrag Nr.: 26.529.707 von buxte am 28.12.06 22:22:06

So das war's dieses Jahr.

3-Jan-06 1,262,400 3.88
29-Dec-06 2,620,266 4,10

ATH 8,39

Sehen wir mal wie das weitergeht.

Alles Gute in 2007

[buxte]

ich wünsche Euch und euren Familien ein Mega- erfolgreiches Jahr 2007, verbunden mit einer totalen Gesundheit, Zufriedenheit und immer einen Euro mehr in der Tasche als ihr ausgeben könnt.

buxte

[URANI]

[bonscott_80]

findet morgen, 13. Februar mit Beteiligung von nvax statt:
BIO CEO & Investor Conference - Jährliche Konferenz.

Kennt jemand die Ergebnisse und die Auswirkungen von 2006?

[powerchord]

Antwort auf Beitrag Nr.: 27.655.853 von bonscott_80 am 12.02.07 11:00:54

news von novavax

NVAX: Pre-Clinical Vaccine Study Published In the journal Vaccine
Knobias via Comtex- 22 minutes ago.
clip|unclip



Novavax, Inc. (NVAX) seasonal influenza vaccine produced robust and broad immune responses compared to other influenza vaccine types, according to a pre- clinical study published in the journal "Vaccine."

In the study, which appears in the online edition of the peer-reviewed journal "Vaccine," mice and ferrets were inoculated with Novavax's virus-like particle ("VLP") vaccine. The VLP vaccine produced antibody responses that were between 1.8 and 7.4 times greater than antibody responses triggered by the comparator vaccines.

"Our VLP can mimic a live virus without infecting the host," said Dr. Rick Bright, lead author of the study and Novavax's vice president of global influenza programs. "These data are important because they show that the immune responses triggered by VLP vaccines may be broader than those from traditional vaccines."

KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.

[backbones]

Antwort auf Beitrag Nr.: 27.877.421 von powerchord am 21.02.07 15:36:47

...bin mal gespannt,wann sich diese news auf den kurs auswirkt.letztes jahr um diese zeit standen wir bei 8$. wait & see

greets backbone

ps. shortvolumen ist enorm hoch, mehr im yahoo us-board

[mikel_ann]

Das ist ja erstaunlich wie positiv die Beteiligung eines
ex-Chiron Präsidenten an NVAX gesehen wird. Bin dennoch gespannt
ob das nachhaltige Wirkung zeigt.

Zudem werden hier gerade mal ein paar Shorties gegrillt

[derwolf1]

@all

Weiß jemand etwas darüber was aus dem
Hepatitis E Virus Vaccine Programm in Phase 3
geworden ist.

Finde ich nicht mehr auf der Homepage...........

[2Tuvok]

Freut sich wohl keiner?

[worldofmoney]

OHH doch cih freu mich schon riesig.
Konnte ja meinen Augen kaum trauen.

Aber noch mehr freu ich mich wenn das der Anfang zum Aufstieg wird.

Da bin ich ja mal gespannt..

[BeastyBloom]

gibt es irgendwelche News zu Novavax?

Greetz

[idon]

Antwort auf Beitrag Nr.: 27.887.059 von backbones am 21.02.07 21:57:18

letztes Jahr gabs die Vogelgrippe und NVAX wurde als einer der Tophersteller für Vaccines angesehen. Hat sich jedoch nicht bestätigt und andere waren schneller, seitdem gings bergab, 8 USD sind Gschichte.

Denke aber, dass die Firma ein gutes Börsenmarketing führt und der Kurs bald wieder Richtung Norden geführt wird. Ist halt ne Zockeraktie Man kann hier gute Geld machen, aber auch verlieren


Greets, Idon

[chri999s]

Press Release Source: Novavax Inc.


Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
Thursday May 3, 8:30 am ET
Ferret Study to be Part of Data Package Required to Begin Clinical Trials


ROCKVILLE, Md., May 3 /PRNewswire-FirstCall/ -- Novavax Inc. said today that it has received positive study results from a live virus challenge to ferrets inoculated with its pandemic influenza vaccine, paving the way for clinical trials to begin on schedule later this year.


In the study, ferrets were inoculated with the company's virus-like particle (VLP) vaccine made from an Indonesian strain of H5N1 avian influenza. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live H5N1 virus. All ferrets that received the Novavax vaccine survived, even those that received the lowest dose.

"These are our most important data to date," said Dr. Rick Bright, Novavax's Vice President of Global Influenza Programs. "We are looking forward to beginning our first clinical trial, which will be a major milestone for Novavax."

According to the study, ferrets that received Novavax's H5N1 vaccine were protected not only against the Indonesian strain of avian flu but also were cross-protected against a separate strain originating in Vietnam. Again, all ferrets that received the Novavax vaccine survived.

The ferret study was conducted in collaboration with the Southern Research Institute of Birmingham, Ala., a facility approved for handling highly lethal avian influenza viruses, and the University of Pittsburgh.

"We are on target to file our first vaccine investigational new drug ("IND") application by mid-year," said Novavax President and Chief Executive Officer Dr. Rahul Singhvi. "Given the robust results we have now received from the ferret challenge study, we are enthusiastic that we have a valuable new vaccine candidate to take into clinic trials."

Ferrets infected with influenza experience symptoms similar to humans, including runny noses, fevers, lethargy and weepy eyes. The ferret has proved to be the most predictive rodent model for success in human clinical trials for influenza.

"Novavax's proprietary vaccine may be the very first VLP vaccine for influenza to enter human clinical trials," Dr. Singhvi said. VLPs mimic the three-dimensional structure of a virus but do not contain genetic material, so they cannot replicate or cause infection. As VLPs maintain functional properties of both influenza surface proteins (hemagglutinin and neuraminidase), they likely trigger multiple arms of the immune system to generate a broadly protective immune response.

About Novavax Inc.

Novavax Inc. (Nasdaq: NVAX - News) is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome® adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues, operating expenses, and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Novavax to secure and maintain relationships with collaborators; risks relating to the early stage of Novavax's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward- looking statements.




--------------------------------------------------------------------------------
Source: Novavax Inc.

[daqsty]

Hallo hat jemand den link zur Homepage von Novovax Danke

[daqsty]

Antwort auf Beitrag Nr.: 29.405.058 von daqsty am 21.05.07 16:12:49

Danke ich hab sie gefunden

[mikel_ann]

Press Release Source: Novavax Inc.


Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
Friday June 1, 8:30 am ET
Study Presented at Second International Conference on Avian Influenza at France's Pasteur Institute


PARIS, June 1 /PRNewswire-FirstCall/ -- Very low doses of Novavax Inc.'s pandemic influenza vaccine provided protection against a lethal challenge of live H5N1 viruses, according to pre-clinical data presented here today at the Second International Conference on Avian Influenza in Humans.
ADVERTISEMENT


The data show that two 0.6 microgram doses of Novavax's virus-like particle (VLP) H5N1 vaccine -- without the addition of an adjuvant -- protected ferrets from challenges with live H5N1 bird flu viruses. This dose is 25 fold lower than the average human dose for most seasonal flu vaccines and more than 100 times lower than other H5N1 vaccines against avian influenza. Novavax plans to submit an investigational new drug application to the U.S. Food and Drug Administration in mid-2007 to commence human clinical trials with the novel H5N1 influenza vaccine.

"We are extremely encouraged that even very low doses of our vaccine are proving to be effective in pre-clinical models without the need for adjuvants," said Dr. Rick Bright, Novavax's Vice President of Global Influenza Programs. "This may be important in a pandemic, where the vaccine supply could possibly need to be 'stretched' to meet the significant global demand."

In the study, ferrets were inoculated with a range of doses of the company's VLP vaccine made from an Indonesian strain of H5N1 avian influenza. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live H5N1 virus, and all survived. The typical human dose of a seasonal influenza vaccine is 15 micrograms. Other pandemic vaccines with no adjuvant have shown only modest levels of immunogenicity in humans with doses as high as 90 micrograms. In this study, ferrets received either 15, 3 or 0.6 micrograms of Novavax's vaccine, and all immunized animals had similar survival results.

In addition, ferrets were protected not only against the Indonesian strain of avian flu but were cross-protected against a separate challenge strain originating in Vietnam. Again, all ferrets that received the Novavax vaccine survived, even those that received the lowest 0.6 microgram dose.

The International Conference on Avian Influenza in Humans brings together leading bird flu experts at the Pasteur Institute to review and discuss the latest scientific advances in vaccine prevention strategies and treatments designed to stem a pandemic.

The U.S. Centers for Disease Control and Prevention currently is testing antibodies from these animals against a number of additional strains of H5N1 that have been detected in recent years to establish whether the vaccine is even more broadly cross-protective.

"We are eager to begin our human clinical trials so that we can continue to evaluate the immunogenicity of our vaccine," Dr. Bright said. "The goal of prevention in a pandemic setting is to be prepared with a vaccine that can protect against varying strains of the virus that mutate as they travel around the globe, and to have enough supply to protect vulnerable populations. We believe our VLP vaccine may provide a unique solution to this potential public health threat."

VLPs mimic the three-dimensional structure of a virus but do not contain genetic material, so they cannot replicate or cause infection. As VLPs maintain functional properties of both influenza surface proteins (hemagglutinin and neuraminidase), they have been shown to activate multiple arms of the immune system to generate a broadly protective immune response.

"We continue to learn more about the potency of our VLP based flu vaccines, which have been shown to induce broadly reactive antibodies, provide efficacy against drifted flu strains, and elicit both B cell and T cell responses," Dr. Bright said. "This information is being used to design clinical studies that have the potential to demonstrate the advantages of the VLP flu vaccines in humans."

About Novavax Inc.

Novavax Inc. (Nasdaq: NVAX - News) is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome® adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, safety, efficacy and potency of our vaccines, and supply availability are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Novavax to secure and maintain relationships with collaborators; risks relating to the early stage of Novavax's product candidates under development; uncertainties relating to commencing clinical trials and their outcome; risks relating to the supply and commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward- looking statements.




--------------------------------------------------------------------------------
Source: Novavax Inc.

[daqsty]

OCKVILLE, Md., July 9 /PRNewswire-FirstCall/ -- Novavax, (Nachrichten) Inc. announced today that is has signed a non-exclusive, worldwide license agreement with Wyeth (Nachrichten), to obtain rights to a patent application covering virus-like particle (VLP) technology for use in human vaccines in certain fields of use. The agreement provides for an upfront payment, annual license fees, milestone payments and royalties on any product sales. Payments under the agreement to Wyeth could aggregate $5 million through the end of 2008.

Novavax is developing pandemic and seasonal influenza vaccines based upon the VLP technology. VLPs mimic the three-dimensional structure of a virus but do not contain genetic material. Therefore, they cannot replicate and are believed to be incapable of causing infection or disease. Because VLPs maintain functional properties of two influenza surface proteins, hemagglutinin and neuraminidase, they have been shown to activate multiple responses in the immune system. The licensed patent application supplements Novavax's extensive patent portfolio in the VLP field.

"We are delighted to have completed this license agreement with Wyeth and see this license as another important step in building a strong intellectual property position for our influenza vaccine programs," stated Rahul Singhvi, President and Chief Executive Officer of Novavax, Inc.

[bonscott_80]

UP - Rating

Scheint sich langsam positiv auszuwirken, heute 6 % , bei allerdings auch sehr fester Nasdaq.


http://www.newratings.com/analyst_news/article_1598630.html

[chri999s]

Novavax Presents Pre-Clinical Data On Recent Advances With HIV VLP Vaccine [NVAX]

8/22/2007 2:52:34 PM Wednesday, Novavax Inc. (NVAX) said results from pre-clinical immunological studies of improved HIV-1 virus-like particle or VLP vaccines show that immunization with VLPs containing a consensus envelope protein is a promising approach to achieving the desired broadly neutralizing antibody response against the HIV-1 virus. The company also said that these data also substantiate the promise of its recombinant VLP technology to design vaccines to ultimately generate an immune response that can prevent complex diseases such as HIV/AIDS. The company presented these results at the AIDS Vaccine 07 conference in Seattle.

Virus-like particles or VLPs represent an attractive HIV-1 vaccine platform for a safe and effective vaccine against HIV/AIDS. VLPs have the potential to mimic the three-dimensional structure of a virus without the risk of replication or infection.

In preclinical studies, VLP vaccination after DNA priming induced HIV-1 neutralizing antibodies to tier 1 viruses that are easy to neutralize and to a select number of tier 2 viruses that are much harder to neutralize.

The study also demonstrated that HIV-1 VLPs formulated without an adjuvant were as potent as an adjuvanted protein subunit vaccine with respect to eliciting neutralizing antibody responses to both tier 1 and tier 2 viruses, the company said.

Novavax said it would support its collaborators in completing pre-clinical studies of the consensus envelope HIV-1 VLP candidate vaccine over the next 12 - 18 months and human clinical trials could begin as early as 2009.

The company is developing vaccines to prevent influenza, HIV and other viral diseases leveraging its proprietary VLP vaccine technology. The company is conducting a Phase I/IIa clinical trial of a pre-pandemic influenza VLP vaccine.

NVAX is currently trading at $3.11.

[powerchord]

Antwort auf Beitrag Nr.: 31.339.371 von chri999s am 30.08.07 11:01:22

vorbörslich schon auf 3,60USD. NVAX ist wieder auf dem Weg nach oben. denke daß wir im 4.quartal die 5USd wieder von oben sehen werden. updates bzgl aids vaccines und birdflu vaccines stehen für jahresende an. mein persönliches 2-jahresziel liegt bei 15USD

mal sehen was da auf uns zukommt. heute wäre ein schlusskurs über 3,50 8widerstand!!) sehr wichtig

up to the moon!!!!

[powerchord]

Antwort auf Beitrag Nr.: 31.415.602 von powerchord am 06.09.07 15:09:46

die bedrohung unserer welt durch vogelgrippe nimmt stetig wieder zu. von den medien bisher kaum beachtet werden laufende vorfälle in indonesien und sumatra. hoffe NVAX ist darauf vorbereitet und startet mit VLP den Siegeszug gegen diese Geißel des 21.Jahrhunderts. Mein geühl sagt mir: NVAX steht vor dem ganz ganz großen Sprung.

Anbei ein Link zum nachdenken:
http://www.recombinomics.com/News/09060701/Tamiflu_Blanket_T…

einfach in browser kopieren und lesen.........

[powerchord]

Antwort auf Beitrag Nr.: 31.447.301 von powerchord am 07.09.07 19:16:28

http://www.channel4.com/news/articles/world/bird+flu+cull+in…


gerade gelesen. pandemie rückt wieder in den focus in good old germany.

NVAX muß wohl Gas geben mit seinen Vaccinen......

[powerchord]

Antwort auf Beitrag Nr.: 31.501.799 von powerchord am 10.09.07 15:33:54

Vogelgrippe in Deutschland von Regierung nun offizielle bestätigt.
Schlachtung von etwa 205.000 Enten.
Quelle: http://www.finanzen.net/news/news_detail.asp?NewsNr=585509

NVAX dürfte heute wieder grün schliessen. bei der kleinsten positiven news werden wir das 3 dollar niveau endgültig verlassen. die sehne des bogens ist schon bis aufs äusserste gespannt. nciht mehr lange und NVAX wird uns noch viel freude machen. außerdem ist am markt eine klare fokussierung auf biotechs zu merken. mein kursziel für november liegt im bereich von USD 5-6:
WE'LL SEE! dies ist natürlich alles nur meine bescheidene persönliche meinung und soll niemanden zum kaufen auffordern.

have a nice day.....p.s. whyso wie gehts dir so??

[daqsty]

ROCKVILLE, Md., Sept. 12 /PRNewswire-FirstCall/ -- Novavax, (Nachrichten) Inc. announced today that several candidates have emerged from an ongoing discovery program to create a novel vaccine for preventing disease associated with the Varicella Zoster Virus (VZV) in older adults. These candidates have met certain significant scientific criteria established by the Company and are now targeted for pre-clinical development.

Varicella Zoster Virus (VZV) causes herpes zoster, or shingles, which is a skin rash often with painful blisters, and is the same virus that causes chickenpox. Anyone who has had chickenpox can develop shingles because VZV remains dormant in the nerve cells and may re-emerge many years later causing the illness. Shingles may affect any age group but occurs most frequently in adults 60 years of age and older and the immunocompromised. The illness is common, resulting in over one million cases in the United States each year. The primary complication of shingles includes acute pain, called post-herpetic neuralgia (PHN), and occurs in approximately 65% of affected patients. Shingles-associated pain may last months, or even years, and can have a negative impact on quality of life. It is also associated with high rates of hospitalization in older adults. The Advisory Committee on Immunization Practices ("ACIP"), a federal body of immunization experts, currently recommends vaccination for all individuals 60 years of age or older. The potential world-wide market for a VZV vaccine in older adults is estimated to exceed $1 billion annually with currently only one product on the market.

"We believe VZV is a strategic target for Novavax to pursue because of our expertise in infectious disease and our proprietary vaccine and manufacturing technologies," said Dr. Rahul Singhvi, Novavax's President and CEO. "Consistent with our strategy to expand our vaccine pipeline, this new program addresses a significant unmet medical need and represents an important opportunity to enhance shareholder value."

[powerchord]

Antwort auf Beitrag Nr.: 31.547.184 von daqsty am 12.09.07 15:20:22

hallo! diese hammermeldung soll´te reichen uns über die 4 dollarhürde in den nächsten tagen zu heben.

good luck all!!!

[powerchord]

Antwort auf Beitrag Nr.: 31.547.303 von powerchord am 12.09.07 15:30:08

rein chartechnisch sieht es im langzeitchart (5 jahre und mehr ) fantastisch aus. wir haben es hier mit einer inversen kopf-schulter formation zu tun mit einem kursendziel von 25USD. sollte der positive newsflow die nächsten monate anhalten können wir dieses ambitiöse ziel auf 2 jahressicht sogar erreichen.

go NVAX go.....

[mfierke]

Antwort auf Beitrag Nr.: 31.547.303 von powerchord am 12.09.07 15:30:08

die Meldung ist leider verpufft

[powerchord]

Antwort auf Beitrag Nr.: 31.555.831 von mfierke am 13.09.07 09:14:22

hallo mfierke!
was heisst heir verpufft???? wir haben die wichtige 3,50 marke wie butter durchbrochen, liegen in einem stabilen aufwärtstrend, biotechindex geht richtung all time high, novavax hat noch einige asse im ärmel, birdflu ist leider wieder ein thema.............

pass mal auf wenn das update zu den hiv vaccinen kommt was dann hier los ist. also ich bin sehr sehr zufrieden mit diesem kontrollierten aber stetigen anstieg bin bei schwäche sofort bereit nochmals aufzustocken. die beste zeit oktober november für NVAX kommt ja erst noch auf uns zu also etwas mehr geduld sollte man schon haben an der börse wenn man in einem soliden wert mit immensen zukunftschancen investiert ist. die tageszockerei ist nämlich nicht mein ding und gehört nicht zu NOVAVAX

keep the faith and all your shares
bis die tage powerchord

[powerchord]

Antwort auf Beitrag Nr.: 31.559.640 von powerchord am 13.09.07 13:46:44

vogelgrippe rückt immer mehr in den fokus bei den medien.
bericht aus china:

China is reporting a potential outbreak of the Bird flu virus in the district of the southern metropolis of Guangzhou that has killed more than 9000 ducks

It is being reported that China has reported a suspected outbreak of the Bird flu virus in ducks.

The outbreak was found in ducks in the district of the southern metropolis of Guangzhou, and since Thursday more than 9500 ducks have died from the virus.

According to the Agriculture Ministry, initial tests confirmed that the ducks that died, did die from the deadly H5N1 strain of the virus.

Samples of dead birds have been sent to a national lab for furthered testing.

In China, 25 human cases resulting in 16 deaths from the virus have been reported since the outbreak was first identified back in November of 2003.

Furthermore, millions of birds have been culled in an attempt to stamp out the presence of the virus in the country.

Quelle: http://www.birdflubeakingnews.com/

Kursentwicklung derzeit unter geringem Volumen gesund und stetig nach oben. heute sollten wir erstmals die 4 usd zumindest tangieren. achtung: jetzt kann es ganz schnell gehen ....

[powerchord]

Antwort auf Beitrag Nr.: 31.627.594 von powerchord am 17.09.07 07:33:16

ausbruch über den widerstand bei 3,75 und dann jump über 4 usd steht unmittelbar bevor nach dieser mustergültigen konsolidierung auf hohem niveau. die 3,70 er marke hat sich als zukünftiger support nach unten etabliert. nächste woche sollten wir mit steigendem umsatz die 4 usd nur mehr von oben sehen. we'll see.

die richtige news dazu und wir greifen die 5 USD an.... NVAX ist für mich ein ganz heisses Eisen im Biotechplay für die nächsten 2-3 Jahre.

Allen Investierten viel Erfolg....

[powerchord]

Antwort auf Beitrag Nr.: 31.682.563 von powerchord am 21.09.07 07:54:42

aus einem anderen forum eine erschreckende nachricht:

Health Care Workers in North Sumatra With H5N1 Symptoms
Recombinomics Commentary
October 9, 2007

two nurses in the Awalbros Hospital, Pekanbaru, Riau, it was suspected was attacked by bird flu after handling the positive patient bird flu was named Linda Tismery.
The bird flu patient who was treated by two nurses died the week end set.
Two nurses who were expected terjangkit bird flu, respectively had the initials S (22) and N (27).

They were appointed as the patient suspect bird flu after experiencing the high and breathless.

The above translation describes two health care workers who developed bird flu symptoms after contact with the most recent confirmed case in north Sumatra, Indonesia. The earlier patient developed symptoms on October 1 and died October 6.

NVAX muß Gas geben wollen wir diese Seuche für die Menschheit noch früh genug stoppen!!!!!!!

Der Uptrend ist charttechnisch derzeit ein Gedicht. Nur eine positive Meldung über einen großen Fortschritt der zahleich laufenden Trials und wir stehen innerhalb weniger Tage wieder bei 5 USD.

[daqsty]

Out of the Gate: Novavax Rises
Wednesday October 31, 10:34 am ET
Novavax Gains Ground on Upgrade to 'Buy' As Analyst Praises Virus-Like Particle Technology

NEW YORK (AP) -- Shares of biotech drug developer Novavax Inc. rose Wednesday morning after an Oppenheimer & Co. analyst upgraded the stock, saying Novavax should report good news from its pipeline and could gain a major partnership due to its vaccine technology.

ADVERTISEMENT
Kevin DeGeeter raised his rating to "Buy" from "Neutral," and set a price target of $6 per share. In December, he said, the company will likely report positive data from an early stage clinical trial of a vaccine designed to treat bird flu. The company may be able to win government contracts for the vaccine, he said.

The Rockville, Md., company is also developing a shingles vaccine, and DeGeeter said it will announce a new vaccine program during the fourth quarter.

Shares rose 38 cents, or 10.8 percent, to $3.90.

Novavax develops some of its drugs using virus-like particle technology. The company says VLP is used to build particles that are similar to viruses, but unable to replicate themselves. That means the patient can develop an immune response to the virus without becoming infected.

"We view Novavax as a next-generation vaccine platform company with a virus-like particle technology that offers the promise of a low-cost and more reliable approach to vaccine manufacturing," DeGeeter said.

As a result, he said, the company could enter a partnership with a large vaccine company in the next year to 18 months.

[powerchord]

Antwort auf Beitrag Nr.: 32.219.810 von daqsty am 31.10.07 15:58:39

nächster schritt sollte ein update im bereich hiv oder birdflu sein. dann erwarte ich mir dass die amerikanische regierung sich mehr mit der vogelgrippe und deren folgen auseindandersetzen wird was unweigerlich zu einer finanzspritze für nvax in 2 stelliger millionenhöhe führen könnte, da deren vlp technik dafür sorgen könnte millionen von menschen im ernstfall zu retten.....alles nur spekulation aber ich glaube hier geht bald so richtig die post ab...we'll see...go nvax go

[powerchord]

Antwort auf Beitrag Nr.: 32.221.564 von powerchord am 31.10.07 17:38:13

nach dieser news kann sich jeder selber ausrechnen wie die pre-clinic dates aussehen werden. up to the moon.....

[powerchord]

Antwort auf Beitrag Nr.: 32.715.579 von powerchord am 10.12.07 16:00:28

GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
via COMTEX

December 10, 2007

* Collaboration aimed at enabling vaccine production facility commissioning in half the time of a traditional egg-based facility.
* Once established, such a vaccine facility could allow manufacturing of pandemic flu vaccine to commence within 12 weeks of the strain isolation

CHALFONT ST GILES, England and ROCKVILLE, Md., Dec 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --

GE Healthcare, a unit of General Electric Company (NYSE: GE), and Novavax Inc. (Nasdaq: NVAX), today announced a collaboration agreement to develop and market a pandemic influenza vaccine manufacturing solution for selected international countries. This collaboration leverages GE Healthcare's bioprocess solutions and design expertise and Novavax's virus- like particle (VLP) and manufacturing platform.

Health planners around the world are looking to increase manufacturing capacity and vaccine stockpiles to counter the threat of a global avian flu pandemic: the global demand for pandemic influenza vaccine has been reported as possibly approaching 13 billion doses, with current world capacity at best 2.4 billion doses.

"This collaboration is a great first example of GE Healthcare realizing its strategy of enabling affordable and safe vaccine production for countries that need to better prepare for emerging infectious diseases," said Peter Ehrenheim, President and CEO, GE Healthcare Life Sciences.

Novavax's VLP-based H5N1 pandemic flu vaccine is currently in Phase I/IIa clinical trials. The goal is that any required recombinant vaccine could be produced in cell culture within 12 weeks of identification of a pandemic strain, without using eggs or live influenza virus -- as little as half the time compared with currently available processes.

Commenting on the collaboration, Dr. Rahul Singhvi, President and CEO of Novavax said, "This collaboration is a critical milestone in addressing one of the most pressing global healthcare issues of the 21st century. We believe the combination of these technologies will enable the creation of a country's rapid response supply and self-sufficiency in pandemic flu vaccine."

GE Healthcare's new ReadyToProcess portfolio of ready-to-use systems and devices is designed to increase speed, simplicity and safety for all areas of bioprocessing, including the time it takes to build and validate a facility. With Novavax's VLP and manufacturing platform, the intention is that it could enable commissioning of a new facility from scratch in approximately two and a half years, half the time for a traditional egg-based vaccine production facility, and at a potential capital reduction of approximately 60 per cent.


eine große news für alle longs die noch dabei sind...

[daqsty]

Novavax sees favorable results from preclinical studies of seasonal flu vaccine

NEW YORK (Thomson Financial) - Novavax Inc. (News) Monday said it had favorable results from preclinical studies of its recombinant trivalent seasonal influenza virus-like particle (VLP) vaccine.

In a study using mice, two injections of Novavax's vaccine showed strong antibody responses against all three influenza subtypes.

The company also said that when all three seasonal influenza VLPs were given as a single trivalent vaccine, the immune response was similar to cases in which each subtype is individually targeted in monovalent formulations.

Novavax said the preclinical study would be included in an investigational new drug submission currently targeted for the second quarter of 2008, with human trials to follow upon clearance from the Food&Drug Administration.

Shares of the Rockville, Md.-based drug delivery and vaccine development company closed Friday at $3.43.

Melinda Peer

[daqsty]

Novavax presents positive influenza results
19th December 2007
By Staff Writer
Novavax has reported favorable results from preclinical studies of its recombinant trivalent seasonal influenza virus-like particle vaccine, which is being developed by using recombinant VLP technology.

The company's pandemic influenza vaccine candidate is currently in Phase I/IIa clinical trials.

In a study using mice, two injections of Novavax's trivalent seasonal flu vaccine without an adjuvant induced strong hemagglutination inhibition (HAI) antibody responses against all three influenza subtypes contained in the vaccine including H3N2, H1N1 and B. The study showed that when all three seasonal influenza virus-like particles (VLPs) were given as a single trivalent vaccine, the immune response to each subtype was comparable to that observed when the VLPs were given in a monovalent formulation.

Rahul Singhvi, Novavax's president and CEO, said: "We are pleased that the results from this seasonal influenza vaccine preclinical study are in line with our expectations. We are aggressively moving this program forward to file an investigational new drug application (IND) as planned in the second quarter of 2008. If filed as anticipated, this would be our second vaccine IND within 12 months of our first vaccine IND, which we filed in June 2007 for our pandemic influenza VLP vaccine."
Print Article Email A Fiend Your Comment Post to del.icio.us Digg this

[daqsty]

Wünsche allen ein frohes und erholsames Weihnachtsfest!!!

[spontanix]

hallo,

ist hier noch jemand von den alteingesessenen?
kann jemand evtl zahlen von estrasorb bringen, was das medikament ungefähr pro jahr gebracht hat?
nun ist ja gestern der verkauf von estrasorb ( mit beibehalt der weltmarktrechten)an garceway bekannt geworden , leider ohne zahlen...
aber was wollen die mit dem cahs machen?
" The asset sale and ongoing production of Estrasorb is expected to generate a modest profit for Novavax, related to this transaction, in 2008. and generate over USD2m of favourable cash flow in 2008 due to non-cash charges against earnings."

[bon_01]

http://de.advfn.com/p.php?pid=nmona&cb=1204905600&article=25…

Sind wohl im Vorfeld schon wieder einige besser informiert, anders kann ich mir den Kursabsturz nicht erklären.

[daqsty]

Novavax to Join Russell 3000 Index
Klicken Sie jetzt

ROCKVILLE, Md., June 26 /PRNewswire-FirstCall/ -- Novavax, (News) Inc. today announced that as of the close of the market Friday, June 27th, it will be included in the Russell 3000 Index, comprised of 3000 of the largest and most liquid stocks based and traded in the United States. Membership in the Russell 3000, which remains in place for a minimum of one year, means the common stock of Novavax will also be automatically included in the small cap Russell 2000 Index.

The Russell 3000 Index is widely used by investment managers and institutional investors for Index funds and as benchmarks for both passive and active investments strategies. The Russell 3000 Index also serves as the U.S. component of the Russell Global Index.

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company creates VLPs by genetically engineering three-dimensional, nanostructures, which incorporate immunologically important lipids and recombinant proteins. Novavax' VLPs resemble a virus by lack the genetic material that would cause infection. Using the Company's proprietary virus-like particle (VLP) technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. The Company also utilizes a unique portable manufacturing system that allows for rapid production of vaccines requiring less infrastructure and represents a potential simpler and more efficient approach to vaccine production. Additional information about Novavax is available at . These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

[Macos]

Guten Morgen

Aufgrund der Kriese am Markt sehe ich jetzt gute Chancen im Biotechsektor....Das abgezogene Geld muss wieder neu investiert werden. Hier sieht es ganz stark nach einem Ausbruch aus?

Darüber hinaus ist Novavax ein sehr interessanter Wert...wenn nur ein Impfstoff am Markt kommt, gibts hier gute Prozente!!!

Gruss macos

[GoofMan]

ROCKVILLE, Md., Dec. 11 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) announced today favorable results from a Phase IIa human clinical trial of its seasonal influenza VLP (trivalent) vaccine candidate. The vaccine, which does not include an adjuvant, induced robust hemagglutination inhibition (HAI) responses, which have been shown to correlate with protection against seasonal influenza disease.

The Phase IIa randomized, placebo-controlled clinical trial evaluated the safety and immunogenicity of different doses of Novavax's seasonal influenza VLP vaccine. Specifically, the vaccine was studied in approximately 300 healthy adults between the ages of 18 to 49 years, who received a single injection of either a placebo or an influenza vaccine at doses of 5 mcg, 15 mcg or 30 mcg per strain.

The adverse events that were reported from the trial are similar in type to those reported for other approved influenza vaccines. Adverse events such as fever, chills, joint pain, muscle aches, headaches, and fatigue were reported at a higher frequency among vaccine as compared with placebo recipients. No serious adverse events have been reported to date. Subjects in the study continue to be monitored for safety through 6 months after vaccination.

The vaccine was immunogenic, inducing HAI responses against the vaccine strains and drifted strains. For subjects in the 15 mcg or 30 mcg vaccination groups, seroprotection rates (i.e., percentage of subjects with HAI titers greater than or equal to 40) for the vaccine strains ranged from 95 to 97% for H3N2, 83 to 94% for H1N1, and 73 to 79% for B. Seroconversion rates (i.e., percentage of subjects with greater than or equal to 4 fold rise in HAI titer from baseline) ranged from 90 to 100% for H3N2, 69 to 78% for H1N1, and 42 to 56% for B among subjects who did not have antibodies to these strains before vaccination. The geometric mean HAI titers were strong and increased with dose. High HAI titers, similar to those seen with the vaccine strains, were also observed against drifted H3N2 and H1N1 strains, demonstrating the potential for the vaccine to be cross-protective.

The current data strongly support continued development of the vaccine. Additional studies of Novavax's seasonal influenza VLP vaccine in healthy adults and subsequently in older adults greater than or equal to 65 years of age in the second half of 2009 to evaluate dosing and further study the safety and immunogenicity of the VLP vaccine as compared with a currently licensed influenza vaccine.

"We are very pleased with the results from this human clinical trial for our seasonal influenza vaccine program," said Dr. Rahul Singhvi, President and CEO of Novavax. "Our VLP technology continues to show promise as an approach against influenza. These seasonal influenza results in combination with the pandemic influenza results released in August of this year, give us ongoing confidence in this technology in preventing influenza. The accumulating immunogenicity data from our preclinical and clinical studies suggest that VLPs may be broadly immunogenic, inducing not only anti-HA responses but also anti-neuraminidase and cell mediated immune responses. We believe these attributes of the VLP vaccine may offer a new approach for a differentiated vaccine to address unmet medical needs related to influenza prevention in elderly patients."

What makes Novavax's seasonal vaccine different

VLPs are recombinant structures that mimic the size and shape of a virus but lack genetic material and are therefore incapable of replication. Because they resemble actual infectious particles presenting proteins in the same conformation as on the wild-type virus, they are able to induce potent immune response. Novavax's VLP vaccine may be differentiated from other influenza vaccines in several ways. First, it includes three viral proteins important for inducing a broad immune response including two surface proteins, hemmaglutinin ("HA") and neuraminidase ("NA"), and a core matrix protein, M1. In contrast, most seasonal vaccines consist almost entirely of HA with little or no NA and M1. The HA protein induces antibody that neutralizes or blocks the growth of the virus; NA induces antibodies that prevent cell-to-cell transmission of virus down the respiratory tract, potentially reducing the severity of influenza disease; and cell mediated immune responses to M1 may lead to destruction of cells already infected. Further, the vaccine is made in cell culture rather than eggs, which permits an exact genetic match to the flu strains causing illness since there is no requirement for adapting the vaccine to grow in eggs.

Novavax's novel manufacturing approach

Novavax's manufacturing process makes it possible to rapidly produce a vaccine that contains strains that are an exact genetic match to the strains circulating in the community causing influenza disease. Novavax's influenza VLPs are produced through recombinant technology in insect cell culture, utilizing a manufacturing process that will consist entirely of disposable, ready-to-use equipment. Current yields are 7 to 10 times higher than those of traditional egg-based or mammalian cell culture manufacturing. Because the Novavax process involves recombinant technology and does not require a live influenza virus, a matched vaccine for the first seasonal influenza clinical trial was manufactured within 12 weeks of identification of the Centers for Disease Control and Prevention ("CDC") released seasonal strains, or approximately half the time required to manufacture egg-based vaccines. The ability to rapidly respond to the identification of annual seasonal strains may be important in providing timely vaccine in advance of annual physicals for children before the school year.

[Uptick08]

Antwort auf Beitrag Nr.: 17.716.466 von whyso am 29.08.05 16:52:58

http://www.bloomberg.com/apps/news?pid=conewsstory&refer=con…

Listen & learn...

[norisbanker]

Unfassbar was sich die letzten Handelsminuten in den USA abspielte - MASSIVE Käufe

[Uptick08]

Antwort auf Beitrag Nr.: 37.059.209 von norisbanker am 29.04.09 08:42:43

und bald auch hier....

Erster Schweinegrippefall in Deutschland

von Lana Stille, Benjamin Dierks (Berlin) und Elke Spanner (Hamburg)Die tödliche Krankheit hat die Bundesrepublik erreicht. Bei einem Patienten aus dem Raum Regensburg wurde die Infektion bestätigt. Verdachtsfälle gibt es in mehreren Bundesländern. Die Seuche ist weltweit auf dem Vormarsch, die Zahl der Toten steigt.


http://www.ftd.de/politik/international/:Ein-Infizierter-in-…

[Uptick08]

http://www.hhs.gov/news/press/2009pres/05/20090522b.html

[Uptick08]

8:04AM Novavax and the NIH agree to evaluate a virus-like particle vaccine candidate against the novel influenza A (H1N1) virus (NVAX) : Co and the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Disease, National Institutes of Health have signed an agreement to cooperate in the evaluation of a virus-like particle (VLP) vaccine candidate against the novel influenza A (H1N1) virus. Novavax has produced influenza A (H1N1) VLP vaccine against the strain recommended by the Centers for Disease Control and Prevention.


Big news for a small NVAX

[Uptick08]

http://www.marketwatch.com/story/biotech-stocks-gain-novavax…


DNDN no. Zwei????....

[Uptick08]

Nun ja..

[Uptick08]

NIH Agrees To Evaluate Novavax' Drug For H1n1 Strain
Published:04-June-2009

By Staff Reporter

A virus-like particle (VLP) vaccine candidate to combat the novel influenza A (H1N1) virus
Suppliers Product News
CCSL Launches www.pharmainteractive.com
The complete learning management solution for the ...
TNO Recognised for Contribution to Heart Disease Prevention
TNO, the Netherlands Organisation for Applied Scie ...
Novavax, and the Division of Microbiology and Infectious Diseases (DMID) have entered into an agreement to cooperate in the evaluation of a virus-like particle (VLP) vaccine candidate against the novel influenza A (H1N1) virus. Novavax has produced an influenza A (H1N1) VLP vaccine against the strain, recommended by the CDC.

The company produced the first batch of H1N1 VLPs in its laboratories in May, three weeks after the CDC announced the genetic sequence of the novel H1N1 virus, which was isolated from an infected person located in California. Novavax' VLPs contain hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins, which were found in this strain.


The size and structure of the VLPs are nearly identical to those of the novel H1N1 virus, but the VLPs are not infectious, as they lack the genes necessary for replication, the company explains.

Novavax has made purified influenza A VLPs, which are being sent to scientists at the CDC and DMID for studies in animal models. The company has also completed genetic engineering and manufacture of the master seed stock necessary to produce larger quantities of the investigational H1N1 VLP vaccine under cGMP conditions.

Rahul Singhvi, President and CEO of Novavax, said: "The company has committed necessary resources to respond as rapidly as possible to construct and manufacture VLP vaccine against this new H1N1 influenza virus. Our proprietary recombinant cell culture technology has enabled production of custom VLPs against this strain of influenza within weeks."

http://www.pharmaceutical-business-review.com/news/nih_agree…

[Uptick08]

Mindestens 30 Kinder der japanischen Schule in Düsseldorf haben sich mit der Schweinegrippe angesteckt...

Das teilte das Gesundheitsamt in Düsseldorf am Donnerstagmorgen mit. Den Kindern gehe es überwiegend gut, zwei von ihnen seien schwerer erkrankt, sagte der Leiter des Düsseldorfer Gesundheitsamtes, Heiko Schneitler. Alle Betroffenen befänden sich zu Hause in Quarantäne. Da weitere Kinder über Beschwerden klagten, sei mit mehr Fällen zu rechnen. Die Ergebnisse lägen am Mittag vor.

Wie die Krankheit eingeschleppt wurde, war vorerst unklar. Zunächst sei ein Sechsjähriger erkrankt, dessen Familie kürzlich Urlaub auf einer Mittelmeerinsel gemacht hatte. Eine Möglichkeit sei, dass er sich auf dem Flughafen angesteckt habe, sagte Schneitler. Davon unabhängig habe es Infektionen bei Schülern der sechsten Klasse gegeben, die am vergangenen Mittwoch, Donnerstag und Freitag einen Ausflug mit dem Bus gemacht hatten. Am Freitag hätten dann einige von ihnen über Fieber, Schnupfen und Heiserkeit geklagt, erklärte Schneitler weiter.

Insgesamt gehen rund 560 Kinder in die japanische Schule. Die Schulleitung erklärte am Donnerstag, die Schule werde bis mindestens Ende nächster Woche geschlossen bleiben. Die Zahl der Schweinegrippefälle in Nordrhein-Westfalen stieg mit den neuen Infektionen auf über 40.

Video

Mehr Videos
In Deutschland sind nach Angaben des Robert-Koch-Instituts derzeit 90 Menschen an der Schweinegrippe erkrankt. Das teilte RKI-Präsident Jörg Hacker am Donnerstag im ARD-Morgenmagazin mit. Er erwarte, dass neue Erkrankungen hinzukämen. Zuletzt seien über zehn Neuerkrankungen am Tag gemeldet worden.

Hacker verwies auf steigende Zahlen im europäischen Ausland: In Großbritannien gebe es über 500 Fälle. Auch in Frankreich und Italien nähmen die Zahlen zu. „Wir haben damit gerechnet, dass auch in Deutschland höhere Fälle zu gegenwärtigen sind."

Weiterführende Links
Die Welt steht kurz vor einer Pandemie
Wichtige Fragen und Antworten zur neuen Grippe
Wenn jeder Kuss zum Judaskuss werden kann
Menschen mit Grippeimpfung besser geschützt
Eine Stadt hält sich für Ursprungsort der Grippe
40 infizierte Schüler in Nordrhein-Westfalen
Alle Informationen über die Schweinegrippe Hacker verwies darauf, dass die Symptome der Viruserkrankung in Deutschland bislang milde ausgefallen seien. Es könne jedoch nicht ausgeschlossen werden, dass die Auswirkungen für die Betroffenen schlimmer würden, wenn sie das Virus verändere. Auch ein tödlicher Verlauf könne dann nicht ausgeschlossen werden.

Weltweit haben sich der Weltgesundheitsorganisation WHO zufolge über 25.000 Menschen mit dem Virus infiziert. In Mexiko starben daran 106 Menschen, in den USA 27. Dort sind die meisten Erkrankungen aufgetreten.

Die Weltgesundheitsorganisation (WHO) hat für Donnerstag eine Dringlichkeitssitzung zur Schweinegrippe einberufen. Die eingeladenen Wissenschaftler sollen darüber entscheiden, ob für die aktuelle Ausbreitung der Schweinegrippe mit dem Virus A (H1N1) Pandemie-Alarm gegeben wird. Sollte die höchste Stufe 6 erklärt werden, gilt die Infektionskrankheit künftig als weltweite Seuche.

Keywords
Deutschland Schweinegrippe Virus H1N1 Grippe Influenza Ausbreitung Im Gegensatz zu einer Epidemie ist eine Pandemie nicht örtlich beschränkt, sondern greift länder- und kontinentübergreifend um sich. Ursprungsland der aktuellen Schweinegrippe ist Mexiko. Dort breitete sich die Krankheit bereits im April rasend aus. Im Laufe der vergangenen Wochen gelangte der Erreger in die unterschiedlichsten Weltregionen.

http://www.welt.de/wissenschaft/medizin/article3903730/Schwe…

[Uptick08]

Zwei überschriften die absolut FUR Novavax sprechen...

H1N1-Virus ist resistent gegen Tamiflu 1.07.2009
http://www.welt.de/die-welt/article4033634/H1N1-Virus-ist-re…

und fast im gleichen Atemzug dieses:

Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 30.06.2009 17:39
http://www.finanznachrichten.de/nachrichten-2009-06/14306700…



und hier der gestrigen Handelsverlauf an der Nasdaq

Naja, der rest könnt ihr Euch denken....

[Uptick08]

3,21$ pre market (High was 3,40)

http://www.nasdaq.com/aspxcontent/ExtendedTradingCharts.aspx…